 
Masonic Cancer Center , University of Minnesota  
Cancer Experimental Therapeutics Initiative (CETI)  
 
 
 
Haploidentical Donor Natural Killer (NK) Cell Infusion with 
Subcutaneous ALT-803 in Adults with Refractory or Relapsed 
Acute Myelogenous Leukemia (AML)    
MT2016- 05 
CPRC # 2016 LS056 
IND #[ZIP_CODE]  
 
University of Minnesota  
Principal Investigato r: 
Claudio Brunstein, MD , PhD  
 
Co-Investigators: 
Jeffrey S. Miller , MD  (IND Sponsor)  
Daniel J. Weisdorf, MD  
David H. McKenna, Jr., MD * 
Veronika Bachanova, MD  
*Will not consent patients  
 
Biostatistician:  
Todd E. De For, MS 
 
 
Participating Affiliate Institution  
Ohio State University (PI - Steven Devine, MD)  
 
 
Version Date:  
January 22, 2019  
 
 
 
 
 
Confidential  
  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 2 of 52  CPRC #2016LS056  Key Study Personnel Contact [CONTACT_625239], 
University of Minnesota  Claudio Brunstein , MD , PhD  
Division of Hematology/Oncology/Transplantation  
[ADDRESS_832963] SE MMC 480 
Minneapolis, MN [ZIP_CODE]  
Phone: 612- 624-3918  
Email: [EMAIL_11941]  
Pager: [ADDRESS_832964] SE  
Minneapolis, MN [ZIP_CODE]  
Phone: 612 626- 5174  
Email:  [EMAIL_9798]  
Fax: [PHONE_12996]  Affiliate Sites 
Manager  
Ohio State University  Steven Devine, MD  
Division of Hematology/Department of Medicine  
B316 Starling-Loving Hall  
[ADDRESS_832965] 
Columbus, OH [ZIP_CODE]  
Phone:  614- 293-5655  
Email:  [EMAIL_11942]  Site PI  
 
[INVESTIGATOR_625214] a complete list of study personnel and contact 
[CONTACT_3031].  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 3 of 52  CPRC #2016LS056  Revision History  
 
Revision 
# Version Date  Detail of Changes  Consent change? (Y/N)  
 07/24/2016  Original version for CPRC  n/a 
 08/24/2016  In response to CPRC stips and Altor’s review  
Other minor edits and clarifications  n/a 
 12/21/2016  Original to IRB and FDA  
Add cytokine release syndrome (CRS)  
• Section 9.3: Add risk of CRS  
• Section 12: Add assessment of CRS with updated 
Targeted toxicity worksheet in appendix V  
• Section 11.2.2: Add PK sampling; CRP/ferritin sample 
collection at 4 time points related to CRS  
Section 12.2: clarify  adverse event documentation  
Section 14.4: change stoppi[INVESTIGATOR_625215] +100 to Day +42  
Other edits through- out protocol including  
Clarify complete remission refers to CR and CRp  
Clarify disease eligibility  
Minor clarifications to inclusion/exclusion criteria  
Update and clarify study SOC and research activities in Section 11  
Update ALT -803 pre- med and monitoring to be consistent 
across protocols  
Add IND number and Jeffrey Miller as IND sponsor  n/a 
1 5/15/2017  In response to FDA comments on other ALT -803 
protocols (for consistency between protocols when applicable):  
• Sections 8.5 and 10.6  – for patients > 100 kg in weight, 
ALT-803 dose calculation will be capped at 100 kg 
• Section 9.6 – revise CRS management plan  
• Section 13.4 – add section regarding regular 
teleconferences between lead institution and affi liate 
sites to facilitate communication between sites  
Additional edits/clarifications from SIV and other reviews:  
• Cover page and page 2 – remove Emory as an affiliate 
site 
• Synopsis and Section 5.2 – make disease eligibility 
criteria  more clear  
• Sections 6.5 and 11.2 - update donor screen panel to 
current panel (replace RPR with treponema, add NAT)  
• Section 8.3 – for product samples to TTL add a 3
rd 
sampling (after depletion but before ALT -803) 
• Section 8.4 – delete statement regarding patient not 
evaluable if requires treatment with steroids  No 
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 4 of 52  CPRC #2016LS056  Revision 
# Version Date  Detail of Changes  Consent change? 
(Y/N)  
• Section 8.5 – clarify that the ALT -803 dose will be 
based on patient weight at admission/pre- chemo, 
update ALT -803 pre meds  
• Sections 11.1and 11.2.2 – Day +14 bm bx is SOC, not 
research 
• Sections 12.1 and 12.6 – align definit ions for deviations 
with  updated MCC definitions  
• Section 12.2 – clarify that a new patient injection 
reaction diary (appendix VI) is to be started for each 
injection site and that the diary is to continue to be 
completed for an injection site until it resolves or the 
form is completed.  
• Section 14.4. – update to reflect single stoppi[INVESTIGATOR_1877]  
• Update appendices to reflect changes within the protocol  
Other minor edits and clarifications  
2 1/22/2019  Change in Principal Investigator  [INVESTIGATOR_625216]2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 5 of 52  CPRC #2016LS056  Table of Contents  
 
Key Study Personnel Contact [CONTACT_7171] ............................................................................................. 2  
Protocol Synopsis  ................................................................................................................................... 7  
Study Schema ........................................................................................................................................ 8  
1 Objectives  ....................................................................................................................................... 9  
1.1 Primary Objective  ............................................................................................................................... 9  
1.2 Secondary Objectives  ........................................................................................................................ 9  
1.3 Correlative Objectives ........................................................................................................................ 9  
2 Background and Significance ......................................................................................................... 9  
2.1 Human Natural Killer (NK) Cells as Mediators of Antitumor Therapy  ......................................... 9  
2.2 NK Cell -Based Immunotherapy for Advanced Malignancies  ....................................................... 9  
2.3 rhIL-15 ................................................................................................................................................ 10 
2.4 IL-15/IL- 15Rα-Fc (ALT -803)  ........................................................................................................... 10 
2.5 ALT-803 by [CONTACT_625240]  ............................................................................................. 11 
3 Study Rationale  ............................................................................................................................ 12 
4 Study Design  ................................................................................................................................ 12 
5 Patient Selection  ........................................................................................................................... 13 
6 Donor Selection  ............................................................................................................................ 15 
7 Patient/Donor Registration  ........................................................................................................... 16 
7.1 Registration with the University of Minnesota Clinical Trials Office .......................................... 16 
7.2 Patients Who Do Not Begin Study Treatment  .............................................................................. 17 
8 Treatment Plan  ............................................................................................................................. 17 
8.1 Preparative Regimen (Day -5 through Day - 2) ............................................................................ 18 
8.2 Donor Leukapheresis (Day -1) ....................................................................................................... 18 
8.3 Preparation of Allogeneic NK Cells / Product Release Criteria  ................................................. 19 
8.4 Allogeneic CD3- CD19- Selected NK Cell Infusion (Day 0)  ........................................................ 19 
8.5 ALT803 (Day 0, +5, and +10)  ......................................................................................................... 20 
8.6 Supportive Care  ................................................................................................................................ 21 
8.7 General Concomitant Medication Guidelines  ............................................................................... 22 
8.8 Duration of Study Participation/Opportunity for Allogeneic Transplant  .................................... 22 
9 Management of Selected Expected Toxicities Associated with NK Cell Infusion and ALT -803 .. 23 
9.1 Tumor Lysis Syndrome.................................................................................................................... 23 
9.2 Acute Allergic Reaction Secondary to the Infusion of Allogeneic NK Cells  ............................. 23 
9.3 Injection Site Reactions/Skin Rash in Association with ALT -803 .............................................. 23 
9.4 Hypotension (systolic blood pressure < 90 mm Hg)  ................................................................... 23 
9.5 Vascular Leak Syndrome ................................................................................................................ 24 
9.6 Cytokine Release Syndrome (CRS) or CRS -Like Symptoms  ................................................... 24 
9.7 Prolonged Marrow Suppression  ..................................................................................................... 25 
10 ALT-803 Formulation, Supply, and Potential Toxicity .................................................................. 25 
10.1 Formulation and Composition  ........................................................................................................ 26 
10.2 Structural Formula ............................................................................................................................ 26 
10.3 Storage and Handling  ...................................................................................................................... 26 
10.4 Stability  .............................................................................................................................................. 27 
10.5 Agent Ordering and Agent Accountability ..................................................................................... 27 
10.6 Study Drug Preparation and Administration  ................................................................................. 27 
10.7 Agent Inventory Records  ................................................................................................................. 27 
10.8 Toxicity  ............................................................................................................................................... 27 
11 Clinical Evaluations and Procedures  ............................................................................................ 29 
11.1 Required Clinical Care Evaluations  ............................................................................................... 30 
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 6 of 52  CPRC #2016LS056  11.2 Research Related Evaluations  ....................................................................................................... 31 
12 Event Monitoring, Documentation, and Reporting  ........................................................................ 34 
12.1 Event Terminology  ........................................................................................................................... 35 
12.2 Event Documentation Requirements  ............................................................................................. 36 
12.3 SAE Documentation and Reporting Requirements  ..................................................................... 37 
12.4 Early Stoppi[INVESTIGATOR_319517]  ............................ 37 
12.5 Other Event Documentation and Reporting Requirements ........................................................ 37 
12.6 Institutional Event Reporting Table  ................................................................................................ 38 
12.7 MCC Reporting Requirements  ....................................................................................................... 38 
13 Study Data Collection and Monitoring  .......................................................................................... 38 
13.1 Data Management  ............................................................................................................................ 38 
13.2 Case Report Forms  .......................................................................................................................... 39 
13.3 Data and Safety Monitoring Plan (DSMP)  .................................................................................... 39 
13.4 Teleconferences – Lead Site and Affiliate  .................................................................................... [ADDRESS_832966] Retention  ............................................................................................................................. 40 
14 Statistical Considerations  ............................................................................................................. 41 
14.1 Study Design, Objectives and Endpoints  ..................................................................................... 41 
14.2 Statistical Analysis  ........................................................................................................................... 41 
14.3 Sample Size  ...................................................................................................................................... 42 
14.4 Stoppi[INVESTIGATOR_625217]  ............................................................................................ 42 
15 Ethical and Regulatory Considerations  ........................................................................................ 42 
15.1 Good Clinical Practice  ..................................................................................................................... 42 
15.2 Ethical Considerations  ..................................................................................................................... 42 
15.3 Informed Consent  ............................................................................................................................. 43 
16 References  ................................................................................................................................... 43 
Appendix I – Eligibility Checklist – Patient  ............................................................................................ 45 
Appendix II – Eligibility Checklist – Donor  ............................................................................................ 47 
Appendix III - Performance Status Scale  ............................................................................................. 48 
Appendix IV – Expected Toxicities of the Preparative Regimen .......................................................... 49 
Appendix V – Targeted Expected Toxicities Worksheet  ...................................................................... 50 
Appendix VI – ALT-803 Injection Site Reactions Diary  ........................................................................ 51 
 
  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 7 of 52  CPRC #2016LS056  Protocol Synopsis  
Haploidentical Donor Natural Killer (NK) Cell Infusion with Subcutaneous ALT -803 in 
Adults with Refractory or Relapsed Acute Myelogenous Leukemia (AML)   
 
Study 
Design:  This is a multi -institutional  Simon’s optimal two -stage single arm phase II trial  of CD3/CD19 depleted, 
ALT-803 activated, haploidentical donor NK cells  and subcutaneous ALT -803 given after  
lymphodepleting chemotherapy (CY/FLU) for the treatment of  refractory or relapsed acute 
myelogenous leukemia (AML).  
 
The primary objective is to study the potential efficacy of NK cells and ALT-803 to achieve complete 
remission (CR/CRp) with or without platelet recovery  by [CONTACT_2006] 42 while maintaining safety . CRp is 
defined as leukemia clearance (< 5% marrow blast and no cir culating peripheral blasts) and neutrophil 
recovery but with incomplete  platelet recovery .  
 The two stage design will enroll 9 patients in stage 1. If 3 or more of the 9 patients achieve CR/CRp 
by [CONTACT_2006] [ADDRESS_832967] NK cell infusion, an additional 15 patients will be enrolled in stage 2 to obtain a more 
precise estimate of CR/CRp . If 10 or more out of the total 24 patients show clearance, further 
investigation will be considered.  
 Patients  are followed for 1 year from the NK cell infusion to determine disease free survival, treatment 
related mortality, and time to relapse.   
 Patients achieving a complete remission (CR or CRp) and neutrophil recovery (ANC > 500 cells/μl) 
for at least 4 weeks will be considered for allogeneic transplant, independent of this study,  to prolong 
remission.   
 
Primary 
Objective:  To estimate the rate of complete remission (CR/ CRp) by [CONTACT_2006] 42  after the infusion of CD3/CD19 
depleted, ALT-803  activated, donor NK cells and subcutaneous ALT-803 given after lymphodepleting 
chemotherapy (CY/FLU)  for the treatment of  refractory or relap sed acute myelogenous leukemia 
(AML)   
 
Secondary 
Objectives:  • To determine the incidence of in vivo expansion ( ≥ 100 donor derived NK cells per µL blood ) of 
NK cells by [CONTACT_2006] + 14 
• To document ALT -803 associated toxicity when given subcutaneously in this patient population  
• To evaluate the safety of the therapy as measured by [CONTACT_625241] (TRM) at 6 months  
Correlative 
Objectives  • To measure the effect of ALT -803 on the function of adoptively transferred NK cells  
• To correlate CR/ CRp with in vivo donor derived NK cell expansion  
• To characterize ALT -803 immunogenicity  
   
Eligible 
Diseases:  Diagnosis of acute myeloid leukemia (AML) and meets one of the following disease criteria:  
Primary induction  failure:    
o De novo AML - no CR after 2 or more chemotherapy induction attempts  
o Secondary AML (from MDS or treatment related): no CR after 1 or more chemotherapy induction attempts   
Relapse after chemotherapy:  not in CR after 1, 2 or 3 re-induction  attempts  
o Patients > 60 years of age, the 1 chemotherapy re-induction  is not required  
Relapse after hematopoietic stem cell transplant:  
o Relapse must have occurred > [ADDRESS_832968] ion attempt is allowed.  
 
Notes:  
1) For hypomethylating agents (i.e. decitabine, azacititdine) to count as an induction/re- induction attempt, the 
patient must have completed a minimum of 3 monthly cycles  
2) For targeting agents (i.e. sorafenib) to count as an induction/re- induction attempt, the patient must have 
completed a minimum of 1 month without attaining CR 
3) 7+3 followed by 5+2 counts as TWO induction attempts  
4) Use of hydroxyurea is permitted to control blasts until Day - 3 per Section 8.7  
5) A history of AML related CNS involvement is allowed if CSF analysis is negative on [ADDRESS_832969] 2 
weeks apart prior to study treatment.  The use of ongoing CNS maintenance therapy is  allowed while on study  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 8 of 52  CPRC #2016LS056   
Key 
Inclusion 
Criteria:  • age ≥18, but ≤ 70 years  
• Karnofsky performance status  ≥ 60% 
• available HLA -haploidentical donor (aged 12 to 75 years) with donor/recipi[INVESTIGATOR_625218] 
a minimum of intermediate resolution DNA based Class I typi[INVESTIGATOR_151592] A and B locus (at least 2/4 class I allele)  
• adequate liver, renal, pulmonary and cardiac function  
• ability to be off prednisone and other immunosuppressive drugs for at least 3 days prior to the NK cell infusion  
• voluntary written consent  
 
Key 
Exclusion Criteria:  • acute leukemia of ambiguous lineage  
• pregnant or breastfeeding  
• new or progressive pulmonary infiltrates  
• active autoimmune disease requiring systemic immunosuppressive therapy  
• history of severe asthma currently  on chronic systemic medications  (mild asthma requiring 
inhaled steroids only is eligible)  
 
Accrual 
Objective:  Stage 1: 9 patients  Stage 2: 15 patients  
Targeted yearly enrollment - 8 patients  
 
Study Schema 
  
 
   
 
  
 
   
 
  
Lymphodepleting Chemotherapy : 
Fludarabine 25 mg/m2 x 5 days  start Day -6 
Cyclophosphamide 60 mg/kg x 2 days on Day -5 and -4  
 
ALT-803 Stimulated  Donor NK Cells : 
The apheresis product (collected Day -1) will be enriched for NK cells with the large- scale CliniMacs ® 
device (Miltenyi) by [CONTACT_465962]3+ cells to remove T -lymphocytes and depletion of CD19+ cells to 
remove B -lymphocytes . The NK cell enriched product will be stimulated by [CONTACT_625242]  
36.1 ng/mL ALT -803 under GMP conditions and infused on Day 0 . 
 
ALT-803 to Facilitate NK Cell Survival and  Expansion: 
ALT-803 at 10 mcg/kg subcutaneously (SC) with the 1st dose administered on Day 0  (no sooner than 
[ADDRESS_832970] NK cells), Day +5 and Day + 10 for 3 doses total    
 
 
 
 
 
Fludarabine  
Cyclophosphamide  
Haplo  ALT -803 
stimulated NK cells  
Evaluate for CR or CRp - 
-6     -5     -4       - 3     -2       -1       0           +5            +10               + 14        +28              +[ADDRESS_832971] 
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 9 of 52  CPRC #2016LS056  1 Objectives  
1.1 Primary Objective  
To estimate the rate of complete remission with or without platelet recovery 
(CR/CRp) by [CONTACT_2006] 42 after the infusion of CD3/CD19 depleted, ALT -803 
stimulated, donor NK cells and subcutaneous ALT-803 given after a non -
myeloablative preparative regimen for the treatment of refractory or relapsed  
acute myelogenous leukemia (AML)     
1.2 Secondary Objectives 
• To determine the incidence of in vivo expansion ( ≥ 100 donor derived NK 
cells per µ L blood) of NK cells by [CONTACT_2006] + 14 
• To document ALT-803 associated toxicity when given in this patient 
population  
• To evaluate the safety of the therapy as measured by [CONTACT_625243] (TRM) at 6 months  
1.3 Correlative Objectives 
• To measure the effect of ALT -803 on the function of adoptively transferred 
NK cells  
• To correlate CR/CRp with in vivo donor derived NK cell expansion  
• To characterize ALT -803 immunogenicity  
 
2 Background and Significance   
2.1 Human Natural Killer  (NK)  Cells a s Mediators o f Antitumor Therapy  
We and others have focused on the role of NK cells in tumor suppression . 
Human NK cells are a subset of peripheral blood lymphocytes defined by [CONTACT_20376]56 or CD16 and the absence of the T -cell receptor (CD3) 
1-10. 
A number of studies suggest that NK cells may have a role in tumor 
surveillance. Cell lines susceptible to NK lysis are designated “NK sensitive” 
targets. The pr ototype target is the hematopoietic cell line K562. Following 
incubation of NK cells with various cytokines, in particular IL- 2, NK cells acquire 
the ability to lyse a broad array of fresh and cultured tumor targets not normally sensitive to NK lysis (NK r esistant targets) including the Raji and Colo cell lines.  
2.[ADDRESS_832972] documented anti -tumor effects in patients using so- called adoptive 
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 10  of 52  CPRC #2016LS056  immunotherapy 11. This approach involves harvesting mononuclear cells from 
patients via lymphapheresis, expansion of the cells ex  vivo using high 
concentrations of the lymphokine I nterleukin- 2 (IL-2), and administration of the 
expanded and IL- 2 activated cells (lymphokine- activated killer, or LAK, cells) to 
the patient along with IL-2 . This approach produced approximately 20% 
complete and partial responses in initial trials at the NCI, with responses 
occurring primarily in melanoma, renal cell cancers, and NHL 12. The MHC -
unrestricted cytolytic activity of LAK cells is mediated predominantly by [CONTACT_625244] 
13. A randomized trial performed at the NCI 11 suggests 
that a portion of the antitumor activity is mediated by [CONTACT_625245], and a portion by [CONTACT_62891]- dose IL- 2 which is apparently required to maintain high 
levels of cytolytic activity 
14. Our recent study demonstrated that adoptively 
transferred NK cells could expand in vivo , and that induction of remission in 5 
of 19 poor -prognosis AML patients was associated with NK expansion and KIR 
ligand -mismatch don ors 15.  
2.3 rhIL- 15  
Interleukin- 15 (IL- 15) is a cytokine and growth factor capable of expanding 
activated T cells and NK cells. By [CONTACT_625246], the NCI Immunotherapy Workshop (2007) ranked IL- 15 as the #1 agent with “high potential for 
immunotherapy
16.”  Based on preclinical non- human primate and early phase 
clinical trial data, including those at the University of Minnesota, IL- 15 regimens 
can unquestionably be designed to prospectively and reproducibly increase T -
cell and NK -cell counts.  
 
The NCI Biolog ical Resource Branch has manufactured E. coli -expressed 
recombinant human IL -15 (rhIL- 15), and this is the first IL -[ADDRESS_832973] tested 
here at the University of Minnesota. Systemic administration of NCI rhIL- 15 by 
[CONTACT_625247] (IV) bolus has been shown to increase the number of 
circulating CD8+ T and NK cells, but the cytokine has a very short half -life. We 
have established the MTD for NCI -manufactured rhIL- 15 using IV and 
subcutaneous dosing. Although safer with subcutaneous administration 
allowing more drug delivery, we identified limitations with the rhIL- 15 in clinical 
testing. Specifically, high levels of free rhIL- 15 decrease circulating IL- 15Rα, 
acting as a negative feedback signal to reduce further IL- 15 trans -presentation . 
This is the rationale in this trial for using IL-15/IL -15Rα-Fc (ALT -803), an IL- [ADDRESS_832974] that physiologically trans -presents  IL-15. 
2.4 IL-15/IL -15Rα-Fc (ALT -803) 
This trial will evaluate an alternative IL- [ADDRESS_832975] a 
prolonged serum half -life. The novel IL- 15 immunoconjugate, ALT -803, was 
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 11  of 52  CPRC #2016LS056  developed by [CONTACT_301407], Altor BioScience Corporation (Altor, Miramar, 
FL), to overcome some of the biologic, regulatory, and commercial limitations of monomeric NCI rhIL -15. Under natural circumstances, IL- 15 and IL- 15 
Receptor -alpha (IL- 15R) are coordinately expressed by [CONTACT_488]- presenting 
cells (i.e., monocytes and dendritic cells) 
17. During signaling by [CONTACT_24977]- [ADDRESS_832976], IL- 15 bound to IL -15R is presented in trans to neighboring NK or 
CD8+ T cells expressing only the IL- 2R receptor. At the immunologic synapse, 
IL15 trans -presentation appears to be a dominant mechanism for IL -15 action 
in vivo, providing tight physiologic control over the functions of IL -15 under 
homeostatic conditions and in response to immune stimuli 18. ALT -803 is a 
soluble complex consisting of two protein subunits of a human IL- 15 variant19 
associated with high affinity to a dimeri c human IL -15 receptor α (IL- 15Rα) 
sushi domain/human IgG1 Fc fusion protein 20. 
  The IL -15 variant is a 114 aa polypeptide comprising the mature human IL- 15 
cytokine sequence with an Asn to Asp substitution at position 72 of helix C (N72D)11. The human IL-15Rα sushi domain/human IgG1 Fc fusion protein 
comprises the sushi domain of the human IL -15 receptor α subunit (IL- 15Rα) 
(aa 1- 65 of the mature human IL- 15Rα protein) linked with the human IgG1 
CH2-CH3 region containing the Fc domain (232 amino acids) . Aside from the 
N72D substitution, all of the protein sequences are human. ALT-803 has a 
prolonged serum half -life in preclinical animal models and has a 4- fold increase 
in biologic activity greater than wild- type IL -15 (IL -15 wt) 
19.  
2.[ADDRESS_832977] 2016, Altor prepared a Safety Summary of ALT -803 based on several 
ongoing early stage trials for various cancer indications (unverified/unaudited data) . At the time [ADDRESS_832978] 1 dose of ALT -803, of 
which 35 were by [CONTACT_625248] 26 of those patients treated at the University of Minnesota . Dosing ranged from 1 mcg/kg to 20 mcg/kg with 
the majority treated at 6 mcg/kg (n=16) and 10 mcg/kg (n=12) . A summary of 
ALT-[ADDRESS_832979] notable event, often 
quite widespread; however none were dose limiting . Typi[INVESTIGATOR_625219] [ADDRESS_832980] -injection . Other effects included fever, fatigue, and changes in 
blood pressure.  
 
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 12  of 52  CPRC #2016LS056  3 Study Rationale   
Patients with poor prognosis acute myelogenous leukemia (AML) cannot be cured 
with standard therapy . This protoc ol is based on previous University of Minnesota 
protocol s testing adoptive transfer of NK cells to treat patients with advanced 
leukemia who failed standard therapi[INVESTIGATOR_014] . Allogeneic NK cells, which are not 
suppressed through inhibitory receptor recognition of  “self” class I MHC molecules 
expressed on cancer cells, may effectively treat these leukemias . We have 
extensive experience using adoptive transfer of haploidentical NK cells and IL- 2 
following lymphodepleting chemotherapy (cyclophosphamide and fludarabin e) and 
find that 30- 50% can achieve a remission and proceed to best donor transplant . 
IL-[ADDRESS_832981] salvage therapy for 
patients with refractory leukemia (expected CR rate of 10%),  they suggest  that 
adoptive cell therapy in its current form requires additional anti -tumor activity  21. 
The limitations of our prior approaches include the lack of in vivo  NK cell expansion 
in most possibly due to the stimulation of Treg by [CONTACT_8668]-[ADDRESS_832982] to IL- 2, 
does not support the expansion of regulatory T cells (Tregs) . We now know that 
IL-[ADDRESS_832983] 
ALT-803 in patients with refractory AML.  
 
4 Study Design  
This is a multi- institutional, Simon’s optimal two- stage single arm phase II trial of 
CD3/CD19 depleted, ALT -803 activated, donor NK cells and subcutaneous ALT -
803 given after lymphodepleting chemotherapy (CY/FLU) for the treatment of 
refractory or relapsed acute myelogenous leukemia (AML) . The primary objective 
is to study the potential efficacy of NK cells and subsequent ALT-803 dosing to 
achieve complete remission (CR) with or without platelet recovery ( CRp) by [CONTACT_2006] 
42 while maintaining safety . CR is defi ned as ≤5% blasts in the bone marrow with 
recovery of neutrophils and platelets. CRp is de fined as leukemia clearance (< 5% 
marrow blast and no circulating peripheral blasts) and neutrophil recovery but with incomplete platelet recovery .  
 
The two stage design will enroll [ADDRESS_832984] NK cell infusion, an additional 15 patients 
will be enrolled in stage 2 to obtain a more precise estimate of CR/CRp . If 10 or 
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 13  of 52  CPRC #2016LS056  more out of the to tal 24 patients show clearance, further investigation will be 
considered.  
 
The CD3/CD19 depleted, ALT -803 stimulated  donor NK cells are infused on Day 
0, after a non- myeloablative preparative regimen of fludarabine/  
cyclophosphamide. Subcutaneous  ALT-803 is given on Day 0  (no sooner than 4 
hours after the NK cell infusion), Day + 5 and Day + 10 for a total of 3 doses .  
 
Patients are followed for 1 year from the NK cell infusion for disease free survival 
(DFS), treatment related mortality (TRM), and incidence  of relapse.  
 
Patients achieving a complete remission (CR or CRp) with  neutrophil recovery 
(ANC > 500 cells/μl) for at least 4 weeks will be considered for allogeneic 
transplant, independent of this study, to prolong remission. Follow -up will continue 
for 1 year from the NK cell infusion.  
 
5 Patient Selection  
Study entry is open to patients  18 - 70 years of age  regardless of gender, race,  or 
ethnic background. While there will be every effort to seek out and include minority 
patients, the patient population is expected to be no different than that of other high risk acute myeloid leukemia studies at the University o f Minnesota and the other 
participating institutions . 
 
Inclusion Criteria:  
5.1 ≥18 but ≤  70 years of age   
 5.2 Diagnosis of acute myeloid leukemia (AML) and m eets one of the 
following disease criteria:  
 Primary induction failure:    
o De novo AML - no CR after 2 or more chemotherapy induction attempts  
o Secondary AML (from MDS or treatment related)  - no CR after 1  or 
more  chemotherapy induction attempts   
 Relapse after chemotherapy : not in CR after 1 , 2, or 3 re -induction 
attempts  
o Patients > 60 years of age, the 1 cycle of chemotherapy is not required  
 Relapse after hematopoietic stem cell transplant:   
o Relapse must have occurred > 18 months  after transplant  
o No re -induction required and no more than 1 re- induction attempt  is 
allowed.   
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 14  of 52  CPRC #2016LS056  Notes:  
1) For hypomethylating agents (i.e. decitabine, azacititdine) to count as 
an induction/re- induction attempt, the patient must have completed a 
minimum of 3 monthly cycles  
2) For targeting agents (i.e. sorafenib) to count as an induction/re-induction attempt, the patient must have completed a minimum of 1 month without attaining CR  
3) 7+3 followed by 5+2 counts as TWO induction attempts  
4) Use of hydroxyurea is permitted to control blasts until Day -3 per 
Section 8.7  
5) A history of AML related CNS involvement is allowed if CSF analysis 
is negative on [ADDRESS_832985] 2 weeks apart prior to study 
treatment. The use of ongoing CNS maintenance therapy is allowed while on study . 
 
5.3 HLA-haploidentical  related donor (aged 12 to 75 years) with donor/recipi[INVESTIGATOR_625220] a minimum of intermediate resolution DNA based Class I typi[INVESTIGATOR_151592] A and B locus  (at least 2/4 class I allele)  
 
5.4 Karnofsky Performance Status ≥  60% (appendix III)  
 
5.5 Adequate organ function within 14 days of study registration (28 days for 
pulmonary and cardiac) defined as:  
• Creatinine:   ≤ 2.0 mg/dL  
• Hepatic:   AST and ALT < 3 x upper limit of institutional normal  
• Pulmonary Function:   oxygen saturation ≥ 90% on room air ; PFT’s  
required only if symptomatic or prior known impairment  - must have 
pulmonary function >50% corrected DLCO and FEV1.   
• Cardiac Function:  LVEF ≥ 40% by [CONTACT_51541] , MUGA  or cardiac 
MRI, no uncontrolled angina, severe uncontrolled ventricular arrhythmias, 
or electrocardiographic evidence of acute ischemia or active conduction 
system abnormalities  
 
5.[ADDRESS_832986] 3 days prior to NK cell infusion (excluding preparative regimen pre-medications)  
 5.[ADDRESS_832987] agree to use effective contraception during therapy and for 4 months after completion of therapy  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 15  of 52  CPRC #2016LS056   
5.8 Voluntary written consent prior to the performance of any research  related 
procedures  
 
Exclusion Criteria:  
5.[ADDRESS_832988] at screening  
 
5.11 Active autoimmune disease requiring systemic immunosuppressive therapy  
 
5.12 History of severe asthma and currently on systemic chronic medicati ons 
(mild asthma requiring inhaled steroids only  is eligible)  
 
5.[ADDRESS_832989] be stable/improving (with associated clinical improvement) 
after 1 week of appropriate therapy ( 4 weeks for presumed or documented 
fungal infections) .  
 
5.14 Uncontrolled bacterial , fungal  or viral infections  including HIV -1/2 or active 
hepatitis C/B - c hronic asymptomatic viral hepatit is is allowed  
 
5.15 Received any investigational agent  within the 14 days before  the start of study 
treatment (1st dose of fludarabine)  
 5.16 Prior ALT -803 
 
 
6 Donor Selection 
Donor selection will be in compliance with 21 CFR 1271.  Donor assessment and 
consent process  will occur in the apheresis center or similar donor facility.  
 
6.1 HLA-haploidentical  related donor (aged 12 to 75 years) with donor/recipi[INVESTIGATOR_625220] a minimum of intermediate resolution DNA based Class I 
typi[INVESTIGATOR_151592] A and B loc us (at least 2/4 clas s I allele) - It is r ecognized 
individual institutions may have differing donor age guidelines . This is 
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 16  of 52  CPRC #2016LS056  acceptable as long as no donor is younger than [ADDRESS_832990] 40 kilograms  
6.3 In general good health as determined by [CONTACT_136395]  
6.4 Adequate organ function defined as:  
• Hematologic: hemoglobin, WBC, platelet within 10% of upper and lower limit 
of normal range of test (gender based for hemoglobin)  
 Hepatic:  ALT < 2 x upper limit of normal,  
 Renal:  serum creatinine < 1.8 mg/dl  
6.5 Performance of a donor infectious disease screen panel including CMV Antibody, Hepatitis B Surface Antigen, Hepatitis B Core Antibody, Hepatitis C Antibody, HIV 1/2 Antibody, HTLVA 1/2 Antibody, Treponema and 
Trypanosoma Cruzi (T. Cruzi) plus HBV, HCV, WNV, HIV by [CONTACT_625249] (NAT); or per current standard institutional donor screen – must be 
negative for HIV and active hepatitis B   
6.[ADDRESS_832991] within 7 days of apheresis  
6.7 Voluntary written consent  (and assent if donor < 18 years of age) prior to 
the performance of any research related procedure  
 
7 Patient /Donor  Registration  
To be eligible for registration to this study, the patient must meet each inclusion 
criteria listed and none of the exclusion on the eligibility checklist based on the 
eligibility assessment documented in the patient’s medical record.  
 The eligibility checklist for both the patient and donor will be completed at the time of study registration. 
7.[ADDRESS_832992] and obtaining 
consent, the site study coordinator or designee will register  the patient . The 
donor also is registered  in OnCore. Complete registration information is found 
in the study’s Pr ocedures Manual for Affiliate Sites.  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 17  of 52  CPRC #2016LS056   
Affiliate sites only: At the time of registration, the signed consent will be uploaded into OnCore as an attachment under the appropriate record (patient 
or donor) .  
 
Affiliates are responsible for fulfilling any local  registration requirements . 
7.2 Patients Who Do Not Begin Study Treatment  
If a patient is registered to the study and is later found not able to begin  study 
treatment (beginning with the 1
st dose of fludarabine) , the patient will be 
removed from study and treated at the physician’s discretion. The study staff  
will update O nCore of the patient’s non- treatment status  (off study) . The reason 
for removal from study prior to starting study treatment will be clearly indicated in OnCore. The patient will be replaced to complete enrollment.  
 
8 Treatment Plan  
In order to provide optimal patient care and to account for individual medical 
conditions, investigator discretion may be used in the prescribing of all supportive care drug therapy (i.e. acetaminophen, diphenhydramine,  antimicrobials, etc .).  
 Patients are to receive allopurinol 300 mg PO daily , unless known allergy , 
beginning prior to chemotherapy start and continuing until Day + 14 or as clinically 
indicated. 
  
 
Study 
Day Therapy Protocol 
Section  
-6 Fludarabine 25 mg/m2: 1 hour infusion  8.1 
-5 Fludarabine 25 mg/m2: 1 hour infusion  
Cyclophosphamide 6 0 mg/kg: 2 hour infusion  8.1 
-4 Fludarabine 25 mg/m2: 1 hour infusion  
Cyclophosphamide 6 0 mg/kg: 2 hour infusion  8.1 
-3 Fludarabine 25 mg/m2: 1 hour infusion  8.1 
-2 Fludarabine 25 mg/m2: [ADDRESS_832993] processing  8.1 
8.2, 8.3  
0 NK cell infusion   
ALT-803 10 mcg/kg SQ no sooner than 4 hours after the 
NK cell infusion  8.4 
8.5 
+5 ALT-803 10 mcg/kg SQ  8.5 
+10 ALT-803 10 mcg/kg SQ  8.5 
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 18  of 52  CPRC #2016LS056  8.1 Preparative Regimen ( Day -5 through Day -2) 
The administration of the preparative regimen will follow the institutional  dosing 
guidelines . Dose and/or schedule adjustments consistent with the standard of 
care may be made on an individual patient basis as needed for safety .  
  
Patients are to receive allopurinol 300 mg PO daily , unless known allergy , 
beginning prior to chemotherapy start and continuing until Day + 14 or as 
clinically indicated . 
 Fludarabine is administered as a 1 hour intravenous infusion per institutional 
guidelines once a day for 5 doses beginning on Day -6. 
 Cyclophosphamide  60 mg/kg will be administered as a 2 hour intravenous 
infusion on D ay –5 and Day -4.  
 
Cyclophosphamide dosing is calculated based on ABW ( Actual Body W eight) 
unless ABW is >150% of the IBW (Ideal Body Weight) . Then the dose should 
be computed using adjusted body weight.  
 
Ideal body  weight is calculated using 50kg + [2.3kg x  (height in inches – 60)] 
for men; 45.5kg + [ 2.3kg x  (height in inches – 60)] for women.  
 
Adjusted body weight = IBW + 0.5(ABW -IBW).  
 
Cyclophosphamide  associated h ydration will be given according to 
recommended institutional standards  (recommend starting 12 hours prior to 
cyclophosphamide). 
 
Mesna is given as five divided doses (totaling the daily cyclophosphamide dose 
in mg) with the 1
st dose prior to the cyclophosphamide infusion, then at 3, 6, 9, 
and 12 hours later .  
8.2 Donor Leukapheresis ( Day -1) 
The donor will be scheduled for the morning before the day of the planned NK 
cell infusion to undergo leukapheresis . Peripheral blood mononuclear cells 
(PBMCs) will be collected by a single apheresis over 5 hours as described by 
[CONTACT_625250], et al22. At the time of the apheresis, three 9 or 10 ml green top tubes  
will be collected for research per S ection 11.2.1.  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 19  of 52  CPRC #2016LS056  8.3 Preparation of Allogeneic NK Cells / Product  Release Criteria  
The apheresis product will be T cell -depleted (CD3 -) and B cell -depleted  
(CD19 -) using the Miltenyi Biotec CliniMACS® Cell Selection System and CD3 
and CD19 MicroBeads  and reagent (Miltenyi Biotec, Auburn, CA) . The NK cell 
enriched product will be activated by [CONTACT_625251] 36.1 ng/mL  
ALT-803 under GMP conditions in the treating institution cell processing facility . 
ALT-803 at 36.1 ng/mL is the equivalent of NCI IL- 15 at 10 ng/ml based on the 
chemical conversions . ALT-803 is a bigger molecule requiring and as a result 
a 3.6 fold more is needed to give the same amount of IL- 15 tested previously . 
 
Refer to the chemistry, manufacturing and control (CMC) section of the 
Investigational New Drug (IND) application for additional preparation 
information and lot release criteria.  
 Cell Product Samples to MCC Translational Therapy Lab  
Samples of the cell product from enrolling sites will be sent to the Masonic 
Cancer Center’s Translational Therapy Lab (TTL) for cell function and 
phenotype studies  being performed under a separate protocol . The following 
samples will be collected:  
1) the apheresis unit before processing  
(100 x 106 cells )  
2) the product after depletion, but prior to addition of ALT -803 (10  x 106 
cells) 
3) the final NK cell product (50 x 106 cells ) pulled prior to  calculating lot 
release  
 Both samples will be sent as a single shipment on Day 0  for overnight delivery  
to the Masonic Cancer Center’s Translational Therapy Lab (TTL) . Refer to the 
Laboratory Manual for  shippi[INVESTIGATOR_22026]. 
8.4 Allogeneic CD3
- CD19- Selected NK Cell Infusion (Day 0 ) 
Pre-medications:  Patients should be pre- medicated with acetaminophen 650 
mg PO and/or diphenhydramine 25 mg PO before and 4 hours after the NK cell 
infusion . Corticosteroids should not be used.  
 Infusion guidelines:  The NK cells will be infused without a filter or pump, 
slowly by [CONTACT_625252] 15 minutes, but no more than one hour .    
 
If less than 1.5 x 10
7 MNC /kg are available, then all cells (after quality control 
testing) should be given and the therapy plan will remain the same . Outcomes 
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 20  of 52  CPRC #2016LS056  will not be included i n the primary analysis for these patients  and they will be 
replaced . 
 
Monitoring:  P atients will be monitored for adverse effects of the NK cell 
infusion such as rash, acute allergic reaction, bronchospasm, respi[INVESTIGATOR_4783], and acute vascular leak syndrome . If severe acute reactions occur  
(defined as CTCAE v 4.0 grade 4 - l ife-threatening consequences; urgent 
intervention indicated), the infusion will be stopped.  
 Hydration will be administered per institutional guidelines . Any elevation of 
daily metabolic monitoring w ill be treated with more aggressive hydration, while  
being attentive to fluid overload.  
 Corticosteroids  are to be avoided Day -3 through Day + 14 (during the period 
of in vivo  NK cell expansion)  except for pre -medications for the preparative 
regimen. If absolutely necessary , steroids may be given as clinically indicated  
but aiming for a cumulative dose of systemic steroids ≤  100 mg of 
hydrocortisone per day  during this window .  
8.5 ALT803 ( Day 0 , +5, and +10)  
ALT-803 10 mcg/kg will be administered subcutaneously on Day 0  (no sooner 
than 4 hours after the NK cell infusion), Day + 5 and Day + 10.  
 ALT-803 dosing will be based on a weight obtained at admission/pre-
chemotherapy. . For patients > 100 kilograms weight, the ALT -803 dose will be 
calculated using a weight capped at 100 kg. The dose will be re- calculated in 
subsequent doses in the event of a 10% or greater weight change from the baseline weight .  
 
Injection sites should be rotated per institutional guidelines and each injection 
site separated by [CONTACT_2669] [ADDRESS_832994] dose of ALT -803 will be given no sooner than 4 hours after the NK cell 
infusion in the absence of a grade 4 NK cell infusion related toxicity . If the 
patient experiences  grade 4 infusion related toxicity during the NK cell infusion 
and it resolves to grade 2 or better within the 48  hours, ALT-803 may be started 
late with all planned doses to be given; however the administration of remaining 
2 doses will be shifted to maintain a minimum of 4 days  between dosing .  
 If ALT-803 cannot  be started within 48  hours  after the NK cell infusion,  no ALT -
803 will  be given and the patient will be replaced.  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 21  of 52  CPRC #2016LS056  A window of +2  days for ALT -803 dosing is allowed in the event of scheduling 
issues or patient status ; however all injections must be separated by a 
minimum of [ADDRESS_832995] and be completed by [CONTACT_2006] + 14. Refer to “Dose Hold” 
below.   
 
Monitoring:   Patients will be observed for a minimum of [ADDRESS_832996] 
dose for immediate adverse events . Vital signs (heart rate, blood pressure, 
respi[INVESTIGATOR_1516], temperature, and oxygen saturation) will be documented prior to 
each ALT-803 injection  and then at 30, 60,  and 120 minut es with a ± [ADDRESS_832997]-dose 
monitoring.  
 
Pre medications:  Give acetaminophen [ADDRESS_832998] dose of ALT-803.  
 
Dose modification:  A one -time dose decrease to 6 mcg/kg is allowed if 
recurrent constitutional symptoms seem related to ALT -803 dosing . Patients 
unable to tolerate the reduced dose will be discontinued from further ALT -803. 
Re-escalation of the dose is not permitted.  
 Dose hold:  A [ADDRESS_832999] dose of ALT-803 may be held on the day of a planned dose for 
either of the following situations:  
• the patient has a fever of > 101°F (38.3 °C)  
• if in the opi[INVESTIGATOR_021], holding would be of benefit to the patient  
 The following guidelines must be followed: 1) A minimum [ADDRESS_833000] period is 
required between doses and 2) any dose not given by [CONTACT_2006] + 14 will be skipped. 
8.6 Supportive Care  
Throughout the study, the investigator may prescribe any concomitant 
medications or treatment deemed necessary to provide adequate supportive care. Supportive care may include antibiotics, anti -fungals, analgesics, 
transfusions, growth factors .  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 22  of 52  CPRC #2016LS056  8.7 General Concomitant Medication Guidelines  
Concurrent chemotherapi[INVESTIGATOR_014] (except hydroxyurea) with ALT -[ADDRESS_833001] of care. Topi[INVESTIGATOR_625221] m is permitted .  
 Beta-blockers and other anti -hypertensives may potentiate the hypotension 
and extra caution should be used during ALT -803 regimen treatment period. It 
is recognized, that ALT -803 treatment, like IL -2 and IL- 15, may be associated 
with low blood pressure especially if the patient is not well hydrated.  
8.8 Duration of Study Participation/Opportunity for A llogeneic Transplant  
Patients will be followed for disease response (including those who go to transplant) until disease progression/relapse, then for survival only  to a 
maximum of 12 months from the NK cell infusion unless: 
• consent is withdrawn 
• patient is discharged to hospi[INVESTIGATOR_625222]/or not returning to the study site for 
follow -up – in these cases, follow -up information including date and cause 
of death may be obtained, as available from other sources   
• the patient is unevaluable - if a patient is not evaluable, he/she will be 
followed only until the resolution or stabilization of treatment related toxicity  
• new anti -cancer treatment is started  
 
Formal follow -up ends at 12 months; however for the purposes of IND annual 
reporting, the date and cause of death will be recorded  in OnCore upon 
knowledge in the follow- up tab . 
 Patients  achiev ing a  complete remission (CR or CRp) may be eligible for 
subse quent allogeneic transplant . The transplant will be done independent of 
this study . Patients would continue to be followed for survival through 12 
months from the NK cell infusion.  
 
 
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 23  of 52  CPRC #2016LS056  9 Management of Selected Expected Toxicities  Associated with NK 
Cell Infusion and ALT-803 
See appendix IV for expected toxicities of the preparative regimen and S ection 
10.8 for the expected toxicities of ALT -803. 
9.1 Tumor Lysis Syndrome  
Tumor lysis syndrome is a possible risk associated with therapy o f active 
leukemia. All patients (except those with known allergy) are to receive 
allopurinol 300 mg every day beginning before chemotherapy and continuing until Day +14 or as clinically appropriate.  
9.2 Acute Allergic Reaction Secondary to the Infusion of Allogeneic NK Cells  
Although infusion of donor lymphocytes has not been associated with acute 
allergic reactions, patients will be closely watched for the occurrence of 
hypotension, dyspnea and angioedema during and immediately after the 
infusion.  
 
The NK cell infusion will be stopped if severe acute reactions occurs (defined 
as CTCAE grade 4 - life-threatening consequences; urgent intervention 
indicated) . Refer to NCI Common Terminology Criteria for Adverse Events v 4.0 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#
ctc_40 ).  
9.3 Injection Site Reactions/Skin Rash in Association with ALT-803 
Based on current experience, localized skin rashes are common with 
subcutaneous administration. If a rash occurs and the rash area surrounding 
the ALT -803 injection site is > 6 cm and symptomatic (painful and/or itchy), it 
may be treated (at the discretion of the treating physician) with topi[INVESTIGATOR_2855] 0.05% clobetasol propi[INVESTIGATOR_16847] (i.e. 0.05% Cormax) or 0.1% triamcinolone (i.e., 
Kenalog) cream. Diphenhydr amine may be administered pre- (25-50 mg TID 
orally) and post -dosing (25- 50 mg TID orally x 2 days) of ALT -803 at the 
discretion of the treating physician. Diphenhydramine should be eliminated if 
not tolerated.  
9.4 Hypotension (systolic blood pressure < 90 mm Hg)  
ALT-803 dosing should be held for hypotension (defined as systolic blood 
pressure less than 90 mm Hg) if in the presence of any clinically significant symptoms (in the opi[INVESTIGATOR_021]), until the systolic blood 
pressure reading is stable. If mild dehydration is suspected, an IV fluid bolus 
may be used per standard of care.  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 24  of 52  CPRC #2016LS056  9.[ADDRESS_833002]  been associated with vascular leak syndrome i n our previous 
experience. Nevertheless, patients will be monitored for weight gain (by 
[CONTACT_625253] 3 times per week)  and pulmonary edema during and after the 
ALT-803 administration.  
9.6 Cytokine Release Syndrome (CRS) or CRS -Like Symptoms  
Patients will be monitored for clinical signs and symptoms of CRS through 
routine daily patient assessments and via the Targeted Expected Toxicities Worksheet (appendix V). Refer to Section [ADDRESS_833003] seen immune activation 
syndromes with other IL- 15 products that include fever, CNS toxicities, and 
rash. CRS will be graded using the revised grading system by [CONTACT_43265].
23 
 
CRS Revised Grading System (replaces CTCAE v4 CRS grading)  
Grade  Toxicity Description  
Grade 1  Symptoms are not life threatening and require symptomatic treatment only, e .g., fever, 
nausea, fatigue, headache, myalgias, malaise  
Grade 2  Symptoms require and respond to moderate intervention - Oxygen requirement  < 40% 
or Hypotension responsive to fluids or low dose of one vasopressor or Gr ade 2 organ 
toxicity  
Grade 3  Grade 3 Symptoms require and respond to aggressive intervention - Oxygen 
requirement ≥40% or Hypotension requiring high dose  or multiple vasopressors or 
Grade 3 organ toxicity or grade 4 transaminitis  
Grade 4  Life-threatenin g symptoms  - Requirement for ventilator support or  Grade 4 organ toxicity 
(excluding transaminitis)  
Grade [ADDRESS_833004] 2 of 3 elevations of CPR > 150, IL- 6 > 150, or ferritin 
> 5000 could be consistent with CRS if in the context of persistent grade > 2 
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 25  of 52  CPRC #2016LS056  fever and other associated symptoms (CRS or neurologic). Of the few patients 
we have suspected of CRS during treatment with NK cells and IL- [ADDRESS_833005], 
all had this degree of fever.  
 1) CRS grade 1, continue current setting management  
2) CRS grade 1 for > 24 hours or CRS grade > 2, admit to hospi[INVESTIGATOR_307] (if not 
already inpatient ) 
3) Start methylprednisolone at 100 mg/kg (or equivalent) IV per day for grade 1-2 CRS for 72 hours or earlier if grade >2 neuro symptoms.  
4) Tocilizumab should be administered if grade ≥3 CRS or grade 1- 2 
symptoms not responding to steroids after 72 hours (and without other 
cause of fever identified) or if any upgrade in severity (grade ≥3 CRS or 
neurologic or other per CTCAE v4).  
 Participating centers must have emergency access (same day) to tocilizumab 
to take part  in this trial.  
9.7 Prolonged Marrow Suppression  
Pancytopenia will occur with this regimen and should be treated as follows:  
 Anemia and T hrombocytopenia  are expected in all patients, and they will 
receive standard supportive transfusion care according to transfusion 
committee guidelines or as modified based on clinical parameters. Prolonged anemia or thrombocytopenia are not unexpected will not count towar ds toxicity.  
 
Neutropenia:
   
• Days –7 to +14:  In the absence of severe, uncontrolled infection, G -CSF or 
granulocytes  should be avoided. If the clinical situation warrants growth 
factor use, ALT -803 administration will be stopped and the patient replaced . 
• At Day + 14:  If the ANC is <500/ mm3, G-CSF will be initiated  
 
[ADDRESS_833006] IL- 15 complex, is the working name 
[CONTACT_625264]. Its active ingredient is ALT -803 and its 
pharmacologic class is as a targeted anticancer immunotherapeutic.  
 
ALT-803 has been referred to as IL- 15N72D:IL- 15RαSu/IgG1 Fc complex in 
various preclinical study reports, publications, and other related documents. No 
other names exist for this product, as it is a novel investigational biologic.  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 26  of 52  CPRC #2016LS056  10.[ADDRESS_833007], ALT -803, is formulated in a phosphate buffered 
saline solution. The drug substance is produced by a recombinant mammalian 
cell line and is manufactured without the use of animal derived components. 
The vialed quantitative composition of ALT -803 is listed in the table below.  
 
Quantitative Composition of ALT -803 
Component  Concentration  Amount/Vial  
ALT-803 1 mg/mL  1.2 mg  
Phosphate Buffered Saline 
(PBS)  QS 1.2 mL  
PBS Formulation: Sodium Chloride (USP) 8.18 g/L; Sodium Phosphate Dibasic (USP) 2.68 g/L; Potassium 
Phosphate Monobasic (NF) 1.36 g/L pH 7.4.  
10.2 Structural Formula   
ALT-803 is a soluble complex consisting of 2 protein subunits of a human IL-
15 variant associated with high affinity to a dimeric IL- 15R sushi domain/human 
IgG1 Fc fusion protein. The IL- 15 variant is a 114 aa polypeptide comprising 
the mature human IL- 15 cytokine sequence with an Asn to Asp substitution at 
position 72 of  helix C (N72D) . The human IL -15R sushi domain/human IgG1 
Fc fusion protein comprises the sushi domain of the IL- 15R subunit (aa 1- 65 of 
the mature human IL- 15Rα protein) linked with the human IgG1 CH2- CH3 
region containing the Fc domain (232 amino acids).  Aside from the N72D 
substitution, all of the protein sequences are human. Based on the amino acid 
sequence of the subunits, calculated molecular weight of the complex 
comprising 2 IL- 15N72D polypeptides and a disulfide linked homodimeric IL-
15RαSu/IgG1 Fc  protein is 92.4 kDa. Each IL- 15N72D polypeptide has a 
calculated molecular weight of approximately 12.8 kDa and the IL-
15RαSu/IgG1 Fc fusion protein has a calculated molecular weight of 
approximately 33.4 kDa. Both the IL- 15N72D and IL- 15RαSu/IgG1 Fc prot eins 
are glycosylated resulting in an apparent molecular weight of ALT -803 as 
approximately 114 kDa by [CONTACT_115571] . The isoelectric point 
(pI) determined for ALT -803 range from approximately 5.6 to 6.5. Thus, the 
fusion protein is negatively charged at pH 7. The calculated molar extinction coefficient at A280 for ALT -803 is 116,540 M -1, or 1.26 OD280 for a 1 mg/mL 
solution of ALT -803, or one OD280 is equivalent to 0.79 mg/mL solution of ALT -
803. 
10.3 Storage and Handling 
Study medication is provided in a 2 mL vial containing 1.2 mL of ALT -803 at a 
concentration of 1 mg/mL. Vials are packaged in cartons and shipped to the 
clinical site. Study medication must be maintained at a temperature between 2°C and 8°C.  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 27  of 52  CPRC #2016LS056  10.[ADDRESS_833008] name, strength, manufacturing date, and the study requirement information. 
ALT-803 will be shipped by [CONTACT_625254]. (See the Procedures Manual for Affiliate Sites for 
instructions on how to order ALT -803.)  
10.6 Study Drug Preparation and Administration  
ALT-803 dose calculation will be based on actual body weight . For patients > 
100 kilograms weight, the ALT -803 dose will be calculated using a weight 
capped at 100 kg. The calculated amount of ALT -803 will be drawn into a 
syringe  for subcutaneous injection. The stock concentration is 1 mg/ml . Doses 
will be drawn directly into the  syringe  for injection. If the  total subcutaneous 
dose is great er than 1.5 mL, the dose will be divided into 2- 3 subcutaneous 
injections as needed. 
 
10.7 Agent Inventory Records  
The investigator, or a responsible party designated by [CONTACT_093] (e.g. 
institutional investigational pharmacy), must maintain a record of the inventory and disposition of all agents received from Altor BioS cience Corporation using 
the Study Agent Drug Accountability Record. (See the Study Procedures 
Manual for the for m to use and instructions on how to complete it. )
 
10.[ADDRESS_833009] 2016, 107 patients were treated with ALT -803. A summary of 
exposure by [CONTACT_625255].  
 
  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 28  of 52  CPRC #2016LS056   
Summary of Exposure, by [CONTACT_625256]:   Subcutaneous:   Intravesical:  
Dose  N   Dose  N   Dose  N  
< 1 μg/kg IV  17   1 μg/kg SQ  2   100 μg  3  
3 μg/kg IV  12   3 μg/kg SQ  0   200 μg  3  
6 μg/kg IV  13   6 μg/kg SQ  16   400 μg  18  
10 μg/kg IV  6   10 μg/kg SQ  12   Total  24  
Total  48   15 μg/kg SQ  4   
  20 μg/kg SQ  [ADDRESS_833010] common side effects seen in  studies with subcutaneous (under the 
skin) injections have been change in blood pressure (increase or decrease),  
fever , fatigue and injection site reaction, and skin  rash, which at times has been 
widespread. These localized skins reactions are common (occurring in more 
than 50% of patients ).  
 The study drug ALT -803 can cause many side effects which may be similar to 
the side effects of interleukin- 2 (IL-2), which has  been used for more than [ADDRESS_833011] likely  (greater than 
10% - 1 in 10 patients)  Less likely  (3% to 10% - 1 in 
30 to 1 in 10 patients)  Rarely (< 3% - 1 in 30 
patients)  
• pain and redness at the 
injection site  
• weight gain with swelling of 
hands and feet due to fluid 
retention  
• feeling tired or short of 
breath due to a low red blood count (anemia)  
• increase or decrease in 
blood pressure  
• flu-like symptoms such as 
fever, chills, shaking, headache, stiffness, aching  
muscles and joints  
• increased risk of infection due to a low white blood 
count  
• increased risk of bruising and 
bleeding due to a low platelet count  
• skin rash • heart problems - causing low 
blood pressure, dizziness, 
chest pain or changes in 
heart rhythm (heart beat)  
• changes in liver and kidney function as detected on routine blood tests  
• cough and shortness of breath  
• mouth sores  
• confusion, sleepi[INVESTIGATOR_625223] a history of depression  • allergic reaction  
• temporary thinning of hair  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 29  of 52  CPRC #2016LS056  Risks of ALT -[ADDRESS_833012] likely  (greater than 
10% - 1 in 10 patients)  Less likely  (3% to 10% - 1 in 
30 to 1 in 10 patients)  Rarely (< 3% - 1 in 30 
patients)  
• weakness, headache, 
dizziness  
• vomiting, nausea, loss of 
appetite  
• reduced levels of electrolytes 
as detected by [CONTACT_625257]  
 
 
11 Clinical Evaluations and Procedures  
Scheduled evaluations up to Day 28 may be performed +/ -3 days from the 
targeted date; assessments to be performed after Day 28 may  be done +/ -7 
days of the targeted date . In addition, targeted days may be altered as clinically 
appropriate.  
  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 30  of 52  CPRC #2016LS056  11.1  Required Clinical Care Evaluations   
 Screening 
Within 30 days 
of study 
registration1 During 
preparative 
regimen until 
ANC> 5002 Day 
0 Day 
+5 Day 
+7 Day 
+10 Day 
+14 Day 
+21 Day 
+28 Day 
+42 Day 
+60 Day 
[PHONE_12997] and 12 
months8 
Consent  X             
Screening Assessment  X             
Medical History  X             
Physical Exam  X daily       X X X X X 
Weight  X 3 x week             
Height  X             
Vitals and pulse 
oximetry  X  X X  X        
Performance Status  X        X X  X X 
Toxicity Assessment  X  X X X X X X X X X X X 
HLA typi[INVESTIGATOR_007]  X             
Recipi[INVESTIGATOR_625224]  X             
CBC, diff, plt  X daily X  X  X X X X X X X 
Basic metabolic panel 
(BMP) or equivalent3  daily  
(unless CMP is 
done)   
  
       
Comprehensive 
metabolic panel (CMP) 
or equiivalent4 X weekly  X  
X  
X X X X X X X 
Urine or serum 
pregnancy test  for 
WOCBP5 X    
  
       
BM biopsy and 
aspi[INVESTIGATOR_337]6 X      X  X X  X X 
Disease staging  X      X  X X  X X 
CXR or chest CT scan  X             
Pulmonary Function 
Tests7 X    
  
       
EKG  X             
Echocardiogram , 
MUGA, or Cardiac  MRI X    
  
      
 
1 –within 14 days for labs required for eligibility per S ection 5.5, consent and HLA typi[INVESTIGATOR_625225] 30 day limit   
2 – or as clinically indicated  
3 –basic metabolic panel consists of BUN, creatinine, c alcium , glucose , lytes (CO2, Cl, Na, K)  
4 – comprehensive metabolic panel consists of a lbumin , alkaline phosphatase (ALP) , alanine aminotransferase (ALT) , aspartate 
aminotransferase (AST) , blood urea nitrogen (BUN) , calcium , creatinine, glu cose , lytes (CO2, Cl, Na,, K),  total bilirubin, and 
total protein  
5- women of child bearing potential  
6- collect 30 ml heparinized bone marrow for research at time of all bone marrow biopsies for clinical care (refer to S ection 11.2)  
7 -testing only required if symptomatic or prior known impairment  
8 –formal follow -up ends  12 months after the NK cell infusion  unless  unevaluable, withdraws consent , discharged to hospi[INVESTIGATOR_6125]/not 
returning to study site or starts new anticancer therapy ; however deaths should be recorded upon knowledge per Section 8.8  
 
  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 31  of 52  CPRC #2016LS056  11.2  Research Related Evaluations   
 11.2.1  Donor Research Related  
 
Screen Day of  
apheresis  
Consent  X  
HLA Typi[INVESTIGATOR_007]   X  
Type and Screen ( ABO/RH  
/Indirect Antiglobulin)  X  
BMT Donor Infectious Disease 
Panel  plus NAT testing (HCV, 
WNV, HIV)  X X2 
Donor chimerism  (affiliate only to 
TTL)  X  
Medical History  X  
Physical Exam  X X 
CBC, diff, platelet  X X 
ALT, creatinine  X  
Pregnancy test, if applicable  X X2 
Three 9 or 10 ml green top tubes  
(research related) to TTL   X 
1- including CMV Antibody, Hepatitis B Surface Antigen, Hepatitis B Core Antibody, Hepatitis C Antibody, HIV 
1/2 Antibody, HTLVA 1/2  Antibody, Treponema, and Trypanosoma Cruzi (T. Cruzi) plus HBV, HCV, WNV, 
HIV by [CONTACT_201863] (NAT);  or per current standard institutional donor screen – must be negative for 
HIV and active hepatitis B  
2- repeat if more than 7 days since previous  testin g 
 
 
The research related donor s amples are shipped the day of collection (Monday -
Thursday) for next day delivery to the Masonic Cancer  Center’s Translational 
Therapy Lab  (TTL) . 
 
Refer to the Laboratory Manual for additional details.  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 32  of 52  CPRC #2016LS056  11.2.2 Patient Research Related Evaluations 
Day: 
  Before 
chemo 
start 
 Day [ADDRESS_833013] 4 hours 
after the NK cell infusion  Day +1, 
Day +2, 
Day+3, 
Day+4  Day + 5  Day 
+7 Day 
+9 Day + [ADDRESS_833014] ALT -803 
dose 1  Day 
+14 Day 
+21 Day 
+28 Day 
+42 Day 
+60 Month 
3 
ALT-803   X   X   X       
Toxicity notation 3 X 
X (pre + 
[ADDRESS_833015]) X  
(pre)  X  
(2 hour)  X  
(pre ALT -[ADDRESS_833016])  X  X  
(pre ALT-[ADDRESS_833017])  X     X 
Skin Reaction Diary – 
start day of ALT -803 
injection and continue until 
next injection or for 6 days  
 X   X X  X       
Monitoring for Stoppi[INVESTIGATOR_625226] 42    
Chimerism – PB 
unseperated  X      X   X1 X1 X1 X1 X1  
Calculation of NK cell 
expansion (by [CONTACT_115158])        X   X X X X   
CRP, ferritin4 X X              
Six 9 or 10 ml green 
top tubes    X X     X   X X X X X X 
One 9 or  10 ml of red 
top tube  X X    X (pre ALT -
803) X  X (pre ALT -
803) X X X X X X 
Pharmacokinetics 
(PKs)  5 ml red top (a 
minimum of 2 ml blood 
needed) per time point    X  
(pre ALT -
803)  X X (pre ALT -
803) X X        
Immunogenicity  5 ml of 
serum (1 red top tube)   X        X X     
30 ml heparinized bone 
marrow at time of each 
BM biopsy  X      
   X  X X X X 
1- if donor cells are present at Day 14, chimerism monitoring will recheck D ay 21. If present Day 21, check Day 28, If present, then Day 42 and Day 60 or until gone  
2 - In the event of a CTCAE grade 4 infusion related toxicity (non- hematologic, excluding fever alone) a sample of banked blood will be tested for HADA  
3 – per Section 12.2  
4 – CRP and ferritin testing at these time points are research related to better understand the development (or not) of cytokine release syndrome. CPR and ferritin testing at other time 
points in association with CRS will be SOC as part of clinical care per Section 9.6  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 33  of 52  CPRC #2016LS056  Note: if a patient is not abiding by [CONTACT_134220] ( Section 
11.1), the collection schedule of the toxicity data and research related samples 
may be altered or discontinued on an individual patient basis, as appropriate.   
 It is recognized that with novel therapi[INVESTIGATOR_134159], the timing of 
protocol directed research samples may miss important patient specific events . 
For this reason, up to 3 extra samples for a total of 180 ml of blood may be 
drawn at additional time points that are not specified above.  
 
Samples , other than for immunogenicity  and pharmacokinetics (PK) , are 
shipped the day of collection (Monday -Thursday) for next day delivery to the 
Masonic Cancer Center’s Translational Therapy Lab  (TTL) . Immunogenicit y 
and PK  samples are stored frozen at the study site until the time of batch 
shippi[INVESTIGATOR_625227]’s central laboratory.  
 Refer to the Laboratory Manual for additional details.  
11.2.1  Assessment of Immune Activation (TTL)  
Samples to evaluate lymphocyte number  and phenotype will be collected as 
detailed above for the Masonic Cancer Center Translational Therapy Lab (TTL)  
along with serum (red top tubes) for measure of cytokines that can reflect immune activation.  Donor immune cells  (green top tubes)  and the donor 
apheresis product will used to understand how donor cells  interact w ith patient 
cancer and patient immune system . 
 
Flow cytometry analysis of a fraction of the PBMC will detect surface markers 
that define lymphocyte subsets (NK, NKT, B, and T cells, both CD4 and CD8), 
as well as intracellular markers that define regulatory T cells (Foxp3) and 
proliferating cells (Ki67) . All remaining PBMC will be cryopreserved in 10% 
DMSO and stored in liquid nitrogen for future testing, if subject agreed to future 
storage at the time of initial consent.  
11.2.2  Pharmacokinetics (ALTOR)  
PK analysis  will be performed at Altor BioScience Corporation. Serum samples 
for PK testing will be collected on all patients. The collection schedule is 
specified in the Study Calendar. One 5 mL silicone coated (red top) tube per 
time point will be collected.  
 
The collected blood samples will be processed (centrifuge at 1000- 1500 xg for 
10 minutes) at the study site and the serum portion will be frozen and shipped 
to Altor BioSci ence in batches upon request.  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 34  of 52  CPRC #2016LS056  11.2.3  Immunogenicity  (ALTOR)  
Immunogenicity assays will be performed at Altor BioS cience Corporation. 
Serum samples for immunogenicity testing will be collected on all patients . The 
collection schedule is specified in the Study Calendar . One 5 mL silicone 
coated (red top) tube per time point will be collected.  
 
The collected blood samples will be processed (centrifuge at 1000- 1500 xg for 
10 minutes) at the study site and the serum portion will be frozen and shipped 
to Altor BioS cience in batches upon request for evaluation using validated 
ELISA methods .  
 
12 Event Monitoring, Documentation, and Reporting 
Toxicity and adverse events will be classified and graded according to NCI's 
Common Terminology Criteria for Adverse Events V 4 .0 (CTCAE) and reported 
on the schedule below . A copy of the CTCAE can be downloaded from the 
CTEP home page 
(http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#
ctc_40 ). 
 An exception to the use of CTCAE will be for the assessment of cytokine 
release syndrome (CRS). Individual adverse events which are associated with 
CRS will be graded per CTCAE; however the ultimate assessment will be made 
using a revised grading system for CRS as presented by [CONTACT_43265]
23 
 
CRS Revised Grading System (replaces CTCAE v4 CRS grading)  
Grade  Toxicity Description  
Grade 1  Symptoms are not life threatening and require symptomatic treatment only, e .g., 
fever,  nausea, fatigue, headache, myalgias, malaise  
Grade 2  Symptoms require and respond to moderate intervention - Oxygen requirement  < 
40% or  Hypotension responsive to fluids or low dose of one vasopressor or Grade 2 
organ toxicity  
Grade 3  Grade 3 Symptoms require and respond to aggressive intervention - Oxygen 
requirement ≥40% or Hypotension requiring high dose  or multiple vasopressors or 
Grade 3 organ toxicity or grade 4 transaminitis  
Grade 4  Life-threatening symptoms  - Requirement for v entilator support or  Grade 4 organ 
toxicity (excluding transaminitis)  
Grade 5  Death  
Grades 2 -4 refer to CTCAE v4.0 grading.  
 
The following definitions of adverse events ( AEs) and serious adverse events 
(SAEs ) will determine whether the event requires expedited reporting via the 
OnCore SAE Report Form in addition to routine documentation in the OnCore 
AE case report form (CRF).  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 35  of 52  CPRC #2016LS056  The reporting timeframes for SAEs and other reportable events are located in 
Section 12. 6. 
 
Note:  throughout this section the generic term “ study drug” refers  to the study 
related treatment (the preparative regimen, NK cell infusion, ALT -803 
injections).  
12.1 Event Terminology  
Adverse Event:   Any untoward medical occurrence associated with the 
use of a drug in humans, whether or not c onsidered drug related.  
 
Serious Adverse Event:   An adverse event is considered “serious” if, in 
the view of either the investigator or sponsor, it results in any of the following outcomes:  
• Death  
• A life -threatening adverse event  
• Inpatient hospi[INVESTIGATOR_1081]  
• A persistent or significant incapacity or substantial disruption of 
the ability to conduct normal life functions  
• A congenital anomaly/birth defect  
• Important medical events that may not result in death, be life-threatening, or require hospi[INVESTIGATOR_89401], based upon appropriate medical judgment, they may jeopardize the patient or subject and may require medical or 
surgical intervention to prevent one of the outcomes listed in this 
definit ion.  
 
Unexpected Event:  An adverse event or suspected adverse reaction is 
considered “unexpected” if it is not listed in the investigator brochure or is not listed at the specificity or severity that has been observed; or, if an investigator brochure is not required or available, is not consistent with the risk information described in the general investigational plan or 
elsewhere in the current application, as amended.  
 
Major  Deviation  as defined by [CONTACT_625258]:  A deviation 
or violation that impacts the risks and benefits of the research; may impact subject safety, affect the integrity of research data and/or affect 
a subject’s willingness to participate in the research. Deviations that place a subject at risk, but do not result in harm are considered to be major deviations.    
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 36  of 52  CPRC #2016LS056   
Minor Deviation as defined by [CONTACT_625258]: A deviation 
or violation that does not impact subject safety, compromise the integrity 
of research data and/or affect a subject’s willingness to participate in the 
research.  
12.2 Event  Documentation Requirements  
Due to the intentional clearing of the marrow with chemotherapy as 
preparation for the NK cell infusion, it is expected that all patients will 
experience severe depression of their blood counts and other related toxicities as detailed in appendix IV. There fore, adverse event 
documentation for the purposes of this study will focus on: 
• targeted expected toxicities felt to be related to the NK cell 
infusion and/or ALT -803 – refer to worksheet in appendix V  
o Prior to chemotherapy start  
o Prior to NK cell infusion  
o 1 hour (+/ - 10 min) post NK cell infusion  
o Prior to ALT -803 dose 1 
o 2 hours (± 30 min) post ALT -803 dose 1  
o 24 hours after the NK cell infusion  
o Prior to ALT -803 dose 2 
o 2 hours (± 30 min) post ALT -803 dose 2  
o Day 7  
o Prior to ALT -803 dose 3 
o 2 hours (± 30 min) pos t ALT -803 dose 3  
o Day 14 
• skin reactions as documented in the patient skin reaction diary 
(Appendix VI) – This form is to be completed by a member of the 
research staff while the patient is an inpatient. Each skin reaction diary focuses on a single injection site. That said, in this study on Day +5, a new skin reaction diary form is started for the most 
recent injection; however,  if the Day 0  injection site reaction has 
not resolved its form continues  to be completed  until resolution.  
Refer to instructions in Appendix VI.   
• other adverse events not on the targeted event worksheet felt to 
be related to the NK cell infusion and/or ALT -803 
• unexpec ted adverse events that cannot be attributed to the 
preparative regimen or other causes (i.e. underlying disease, co-
morbidities)  
 
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 37  of 52  CPRC #2016LS056  After Day 14, monitoring for adverse events will become less frequent 
based on the schedule in Section [ADDRESS_833018] possibly related to either the NK cell infusion and/or ALT -803 
will be documented.  
 
Note: if a patient is not abiding by [CONTACT_625259] (Section 11.1), collection of the corresponding targeted events (and 
research related samples) also may be altered or discontinued on an individual patient basis, as appropriate.   
12.3 SAE Documentation and Reporting Requirements  
Any event  meeting the definition of a serious adverse event (SAE) 
requires documentation using the MCC  SAE Report Form in OnCore. 
 Any event that is both serious and unexpected, and at least possibly 
related to the study treatment  must be reported to Masonic Cancer 
Center Affiliate Sites Manager and to Altor BioScience with in [ADDRESS_833019] be reported within 5 working days of 
knowledge. Refer to S ection 12. 6. 
12.4 Early Stoppi[INVESTIGATOR_625228] 4- 5 non -hematologic, non- relapse 
and non- infectious toxicity (except for fevers alone) by D ay [ADDRESS_833020] an early stoppi[INVESTIGATOR_625229] a SAE  and should be reported as such only if they meet the 
criteria for reporting as defined in S ection 12.3.  
12.5 Other Event Documentation and Reporting Requirements  
Deaths, including due to disease, will be recorded as an SAE and reported per S ection 1 2.6. Deaths due to disease should be recorded as 
a Grade 5 “Neoplasms benign, malignant and unspecified (incl cysts and 
polyps) – Other (Progressive Disease) . In addition, the death date and 
cause must be reported in the patient follow -up tab in OnCore using the 
comment field in the survival status section to record the cause.  
 
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 38  of 52  CPRC #2016LS056  12.6 Institutional Event Reporting Table  
Individual institutional sites will be responsible for reporting any event 
meeting local reporting requirements to their institutional IRB and/or 
other research oversight committees.  
 
Event Type  Reporting Timeframe  Form in OnCore 
to Use  Report to  
SAEs Req uiring Expedited 
Reporting (serious, 
unexpected and at least possibly related to ALT -
803) Within 24 hours of 
knowledge  SAE Report 
Form For Affiliate Sites: 
Masonic Cancer Center (MCC) Affiliate Sites Manager  
[EMAIL_11943]
 
 Altor BioScience  at 
[EMAIL_11944]  
 
Local institutional IRB or other 
entities per institutional policies and guidelines  
 
For UMN MCC: Report to the 
study ’s regulatory specialist  All other SAEs  Not required  n/a 
Stoppi[INVESTIGATOR_220943] 24 hours of 
knowledge  Event Form  
Major Deviations  Within 5 working days 
of knowledge  Deviation Report 
Form 
 
12.7 MCC Reporting Requirements  
As the study sponsor, the Masonic Cancer Center  has the following 
expedited reporting responsibilitie s for events reported in Section 1 2.6: 
 
 
13 Study Data Collection and Monitoring 
13.1 Data Management  
This study will report clinical data using The Online Enterprise Research 
Management Environment  (OnCore®), a web based Oracle® database 
utilizing study specific electronic case report forms . Key study personnel are 
trained on the use of OnCore and will comply with protocol specific Agency  Criteria for reporting  Timeframe  Form to 
Use Submission 
address/ fax 
numbers  
FDA 
 Unexpected and fatal or unexpected and  life 
threatening suspected adverse reaction  no later than 
7 Calendar 
Days  MCC SAE  Submit to FDA as 
an amendment to 
IND with a copy to 
Altor Bioscience  
at 
cancer_trial@altor
bioscience.com  
And each affiliate institution  
 1) Serious and unexpected suspected adverse 
reaction or  
2)  increased occurrence of serious suspected adverse 
reactions  over that listed in the protocol or investigator  
brochure or 
3) findings from other sources (other studies, animal 
or in vitro testing)  no later than 
[ADDRESS_833021] the early study stoppi[INVESTIGATOR_1877].  At time of 
reporting Event 
Form  mcc-
[EMAIL_2017]  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 39  of 52  CPRC #2016LS056  instructions embedded within the OnCore . Patient demographics, patient 
specific study treatment calendars, t argeted expected toxicities  and other 
information required for IND annual reporting will be placed in OnCore and 
other research databases maintained by [CONTACT_417942].  
13.2 Case Report Forms  
Participant data will be collected using protocol specific electronic case 
report forms (e- CRF) developed within OnCore based on its library of 
standardized forms . The e- CRF will be approved by [CONTACT_1758]’s Principal 
Investigator [INVESTIGATOR_102631]. The Study 
Coordinator or designee will be responsible for registering the patient into OnCore at time of study entry, completing e- CRF based on the patient 
specific calendar, and updating the patient record until patient death or end of required study participation .  
13.3 Data and Safety Monitoring Plan (DSMP)  
The study’s Data and Safety Monitoring Plan will be in compliance with the 
University of Minnesota Masonic Cancer Center's Data & Safety Monitoring 
Plan (DSMP), which can be accessed at  http://z.umn.edu/dmsp
. 
 For the purposes of data and safety monitoring, this study is classified as 
high risk (under a locally held IND) . Therefore the foll owing requirements 
will be fulfilled:  
 
 At least  quarterly review of the study’s progress by [CONTACT_625260] (DSMC) . 
 The PI [INVESTIGATOR_625230].  
 The Masonic Cancer Center PI [INVESTIGATOR_625231] 12.7 to the Masonic Cancer 
Center’s SAE Coordinator, the University o f Minnesota IRB , and the 
FDA.  
 The PI [INVESTIGATOR_625232], at the time of the continuing review with the University o f 
Minnesota IRB, a copy of the report with any attachments will be submitted to the Cancer Protocol Review Committee (CPRC).  
 
  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 40  of 52  CPRC #2016LS056  IND Annual Reports  
In accordance with regulation 21 CFR § 312.[ADDRESS_833022] .   
13.4 Teleconferences – Lead Site and Affiliate  
Regular teleconferences to facilitate communication between participating 
sites regarding the study’s progress, patient updates, summary of safety 
reports, case report form completion, and other issues for discuss ion. The 
University of Minnesota Affiliate Manager will be responsible for arranging 
these teleconferences and preparing the agenda. Meetings will occur at least every 2 weeks; however, these may be scheduled more or less 
frequently at the discretion of the lead institution. Participation of a minimum 
of one representative from the affiliate site is required. These teleconferences are in addition to other previously described site interactions including centralized patient registration, institutional and MCC 
required reporting of safety related issues, case report form completion in 
the study’s central database (OnCore) and affiliate oversight through self -
monitoring in compliance with the Masonic Cancer Center’s Data and 
Safety Monitoring plan.  
13.5 Affiliate Site Monitoring 
The PI ([CONTACT_625267]) with the CTO has oversight responsibility for trial 
monitoring at affiliate sites . Affiliate sites must  self-monitor following the 
University of Minnesota Masonic Cancer Center Data and Safety Monitoring Plan (DSMP ) http://z.umn.edu/dmsp
 
 
The investigator will permit study -related monitoring, audits, and 
inspections by [CONTACT_1758]’s Principal Investigator /IND sponsor and/or any 
designees, the local IRB, government regulatory bodies, and University of 
Minnesota compliance groups . The investigator will make available all study 
related documents (e.g. source documents, regulatory documents, data collection instruments, study data, etc.) . The investigator will ensure the 
capability for inspections of applicable study -related facilities (e.g. 
pharmacy, diagnostic laboratory, etc.) will be available for trial related 
monitoring, audits, or regulatory inspections.  
13.[ADDRESS_833023] Retention  
The investigator will retain study records including source data, copi[INVESTIGATOR_229444],  consent forms, HIPAA authorizations,  and all study 
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 41  of 52  CPRC #2016LS056  correspondence in a secured facility  for at least  [ADDRESS_833024] the CTO before destroying any study related recor ds. 
 
 
14 Statistical Considerations  
14.1 Study Design, Objectives and E ndpoints   
The primary objective  of this phase II trial is to study the potential efficacy 
of NK cells and ALT -803 to achieve a complete remission (CR or CRp) by 
[CONTACT_2006] 42 while maintaining safety . The primary endpoint, CRp is defined as 
leukemia clearance (< 5% marrow blast and no circulating peripheral blasts)  
and neutrophil recovery  without platelet recovery . CR is defined as ≤5% 
blasts in the bone marrow with recovery of neutrophils and platelets.   
 
Secondary endpoints include :  
• The incidence of in vivo  expansion (≥ 100 donor derived NK cells per uL 
blood) of NK cells by [CONTACT_2006] + 14 
• ALT-803 associated toxicity 
• Treatment related mortality (TRM)  by [ADDRESS_833025] -therapy  
 
The two stage design will enroll 9 patients in stage 1. If 3 or more patients 
show clearance out of 9, an additional 15 patients will be enrolled to obtain a more precise estimate of CR/CRp . If [ADDRESS_833026] errors. Secondary endpoints of in vivo  expansion and various safety /toxicity 
measures will similarly be estimated with simple proportions . Cumulative 
incidence will be used to estimate the probability of treatment  related 
mortality treating relapse as a competing event .
 24 
 
The correlation of CR/ CRp with in vivo  NK cell expansion will be evaluated 
with a chi -square test . The function of adoptively transferred NK cells will 
be measured descriptively with non- parametric statistics such as median, 
range and interquartile range.  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 42  of 52  CPRC #2016LS056  14.3 Sample Size  
The overall sample size of  24 patients is based on Simon’s optimal two-
stage design assuming a type- I error of 5% and 80% power .25 The null 
hypothesis or the rate considered unworthy of further investigation is 25% 
clearance. The alternative hypothesis or the rate considered worthy  of 
further investigation is 50%.  
 
If we reach the second stage, the study will go on to enroll an additional [ADDRESS_833027] 8 patients  per year . 
Therefore,  we anticipate completion of enrollment  within 3 years.
 
14.4 Stoppi[INVESTIGATOR_625233] y will be monitored using an early stoppi[INVESTIGATOR_1877]. The s toppi[INVESTIGATOR_625234] .26 
 Patients with refractory AML are expected to die. Therefore, excess toxicity 
needs to be carefully evaluated. Based on current experience, grade 4- 5 
non-hematologic, non- relapse and non- infectious toxicity (except for fevers 
alone) as defined by  [CONTACT_6812]’s CTCAE version 4 is expected to be about 
10%. The goal is to construct a boundary based on excessive toxicity by 
[CONTACT_2006] [ADDRESS_833028] 10 % if the rate 
is equal to 10% and our sample size is 24. With these stipulations, the study 
will be stopped if there is excess toxicity in 2 out 3 patients,  3 out of 8 
patients, 4 out of 14 patients, 5 out of 21 patients or  6 patients at any time. 
If the actual probability of toxicity  is 30% or 40%, the probability of reaching 
the boundary will be 86 % and 9 8% respectively.  
15 Ethical and Regulatory Considerations  
15.1 Good Clinical Practice  
The study will be conducted in accordance with the appropriate regulatory requirement(s) . Essential clinical document s will be maintained to 
demonstrate the validity of the study and the integrity of the data collected . 
Master files should be established at the beginning of the study, maintained 
for the duration of the study and retained according to the appropriate 
regulations .  
15.2 Ethical Considerations  
The study will be conducted in accordance with ethical principles founded 
in the Declaration of Helsinki . The IRB will review all appropriate study 
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 43  of 52  CPRC #2016LS056  documentation in order to safeguard the rights, safety and well -being of the 
patients . The study will only be conducted at sites where IRB approval has 
been obtained. The protocol, informed consent, written information given to 
the patients, safety updates, annual progress reports, and any revisions to 
these documents will be provided to the IRB by [CONTACT_093] .  
15.3 Informed Consent  
All potential study participants will be given a copy of the IRB -approved 
Consent to review. The investigator  or designee will explain all aspects of 
the study in lay language and answer all questions regarding the study. If the participant decides to participate in the study, he/she will be asked to sign and date the Consent document. Patients  who refuse to participate or 
who withdraw from the study will be treated without prejudice.  
 
[ADDRESS_833029] P. Role of monocytes in the expansion of 
human activated natural killer cells. Blood. 1992;80:2221- 2229.  
2. Miller JS, Verfaillie C, McGlave P. The generation of human natural killer cells from 
CD34+/DR - primitive progenitors in long- term bone marrow culture. Blood. 
1992;80:2182- 2187.  
3. Pi[INVESTIGATOR_98803] B, Miller J, Verfaillie B, McGlave P, Hu W -S. Population dynamics of hu man 
activated killer cells in culture. Biotechnology and Bioengineering. 1994;43:685- 692. 
4. Miller JS, Alley KA, McGlave P. Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma- based long -term culture system: ident ification 
of a CD34+7+ NK progenitor. Blood. 1994;83:2594- 2601.  
5. Miller JS, Klingsporn S, Lund J, Perry EH, Verfaillie C, McGlave P. Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy. Bone Marrow Transplant. 1994;14:555- 562. 
6. Pi[INVESTIGATOR_625235], McGlave PB, Hu WS, Miller JS. Natural killer cell proliferation is 
dependent on human serum and markedly increased utilizing an enriched supplemented basal medium. J Hematother. 1995;4:149- 158. 
7. Pi[INVESTIGATOR_625235], Gupta K, Hu WS, Miller  JS. Human natural killer cell expansion is 
regulated by [CONTACT_625261]- mediated activation of transforming growth factor -beta 
[ADDRESS_833030] and soluble factors. Blood. 
1996;87:180- 189. 
8. Cervantes F, Pi[INVESTIGATOR_625235], McGlave PB , Verfaillie CM, Miller JS. Autologous activated 
natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood. 1996;87:2476- 2485.  
9. Pi[INVESTIGATOR_625235], Europa AF, Hu WS, Miller JS. Production of human natural killer cells for adoptive immunotherapy using a computer -controlled stirred- tank bioreactor. J 
Hematother. 1996;5:475- 483. 
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 44  of 52  CPRC #2016LS056  10. Pi[INVESTIGATOR_625235], Miller JS. CD56+bright and CD56+dim natural killer cells in patients with 
chronic myelogenous leukemia progressively decrease in number, respond less to 
stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on 
a per cell basis. Blood. 1996;88:2279- 2287.  
11. Rosenberg SA. Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. J Clin O ncol. 1992;10:180- 199. 
12. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine- activated killer cells and interleukin-
2 or high- dose interleukin- 2 alone. N Engl J Med. 1987;316:889- 897. 
13. Herberman R, Balch C, Bolhuis R. Lymphokine- activated killer cell activity:  
characteristics of effector cells and their progenitors in blood and spleen. Immunology Today. 1987;8:178- 181. 
14. Maghazachi AA, Herberman RB, Vujanovic NL, Hiserodt JC. In vivo  distribution and 
tissue localization of highly purified rat lymphokine -activated killer (LAK) cells. Cell 
Immunol. 1988;115:179- 194. 
15. Miller J, Soignier Y, Panoskaltsis -Mortari A, et al. Successful adoptive transfer and in 
vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 
2005;105:3051- 3057.  
16. Cheever MA. Twelve immunotherapy drugs that could cure cancers. Immunol Rev. 
2008;222:357- 368. 
17. Steel JC, Waldmann TA, Morris JC. Interleukin- 15 biology and its therapeutic 
implications in cancer. Trends Pharmacol Sci. 2012;33(1):35- 41.  
18. Sato N, Patel HJ, Waldmann TA, Tagaya Y. The IL- 15/IL -15Ralpha on cell surfaces 
enables sustained IL- 15 activity a nd contributes to the long survival of CD8 memory T 
cells. Proc Natl Acad Sci U S A. 2007;104(2):588- 593. 
19. Zhu X, Marcus W, Xu W, et al . Novel Human Interleukin -15 Agonists . J of Immunology, 
2009, 183(6): 3598 –3607.  
20. Han KP, Zhu X, Liu B, et al. IL- 15:IL -[ADDRESS_833031] complex: High-
level co- expression in recombinant mammalian cells, purification and characterization. 
Cytokine . 2011;56(3):804- 810. 
21. Bachanova V, Cooley S, Defor TE, et al. Clearance of acute myeloid leukemia by 
[CONTACT_625262]- 2 diphtheria toxin fusion protein. 
Blood 2014.  
22. McKenna DH, Jr., Sumstad D, Bostrom N, et al. Good manufacturing practices production of natural killer cells for immunotherapy: a six- year single- institution 
experience. Transfusion. 2007;47(3):520- 528. 
23. Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124(2):188- 195.Lin DY.  
24. Lin DY. Non-parametric inference for cumulative incidence functions in competing risks 
studies. Stat Med 1997;16(8):901- 10. 
25. Simon, Richard. 'Optimal Two- Stage Designs for Phase II Clinical Trials', Controlled 
Clinical Trials, 1989, Volume 10, pages 1- 10. 
26. Ivanova A, Qaqish BF, Schell MJ. Continuous toxicity monitoring in phase II trials in 
oncology. Biometrics. 2005;61:540- 545. 
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 45  of 52  CPRC #2016LS056  Appendix I – Eligibility Checklist – Patient   
Haploidentical Donor Natural Killer (NK) Cell Infusion with Subcutaneous ALT -803 in Adults with 
Refractory or Relapsed Acute Myelogenous Leukemia (AML)   
Patient Eligibility Checklist – page 1 of 2  
Patient initials          Patient ID  -   
(site code – seq #)  
 
INCLUSION CRITER IA  
A "NO" response to any of the following disqualifies the patient from study entry.  
  Yes      No  
1.  ≥18 but ≤ 70 years of age       
2.  Diagnosis of acute myeloid leukemia (AML) and meets one of the following disease criteria:  
 Primary induction failure:    
o De novo AML - no CR after 2 or more chemotherapy induction attempts  
o Secondary AML (from MDS or treatment related): no CR after 1 or more chemotherapy  induction 
attempts  
 Relapse after chemotherapy:  not in CR after 1, 2, or 3  re-induction attempts  
o Patients > 60 years of age, the 1 chemotherapy re -induction is not required  
 Relapse after hematopoietic stem cell transplant:  
o Relapse must have occurred > 18 months after transplant  
o No re- induction required and no more than 1 re- induction attempt  is allowed.  
Notes:  
1) For hypomethylating agents (i.e. decitabine, azacititdine) to count as an induction/re- induction attempt, the patient must 
have completed a minimum of 3 monthly cycles  
2) For targeting agents (i.e. sorafenib) to count as an induction/re- inducti on attempt, the patient must have completed a 
minimum of 1 month without attaining CR 
3) 7+3 followed by 5+2 counts as TWO induction attempts  
4) Use of hydroxyurea is permitted to control blasts until Day - 3 per Section 8.7  
5) A history of AML related CNS involvement is allowed if CSF analysis is negative on [ADDRESS_833032] 2 weeks apart 
prior to study treatment. The use of ongoing CNS maintenance therapy is allowed while on study  
      
3.  HLA-haploidentical related donor (aged 12 to 75 years) with donor/recipi[INVESTIGATOR_625218] a 
minimum of intermediate resolution DNA based Class I typi[INVESTIGATOR_151592] A and B locus   (at least 2/4 class 
I allele)       
4.  Karnofsky Performance Status ≥ 60%                                         PS -             
5.  Adequate organ function within 14 days of study registration (28 days for pulmonary and cardiac) 
defined as:  
Test Required Value  Patient’s Value  Date of Test Result  
serum creatinine  ≤ 2.0 mg/d  .  mg/d  / /  
AST  < 3 x upper limit of institutiona l normal  
value:  u/L   u/L / /  
ALT < 3 x upper limit of institutional  normal  
value:  u/L   u/L / /  
oxygen saturation  ≥ 90% on room air   / /  
pulmonary function  (only if 
sxs or know impairment)  >50% corrected DLCO and FEV1  .% / /  
cardiac  LVEF ≥ 40% by [CONTACT_26142], MUGA  or MRI , 
no uncontrolled angina, severe uncontrolled 
ventricular arrhythmias, or ECG evidence of 
acute ischemia or active conduction system 
abnormalities  .% / /  
      
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 46  of 52  CPRC #2016LS056   
Haploidentical Donor Natural Killer (NK) Cell Infusion with Subcutaneous ALT -803 in Adults with 
Refractory or Relapsed Acute Myelogenous Leukemia (AML)   
Patient Eligibility Checklist – page 2 of 2 
Patient initials         
 
INCLUSION CRITERIA  
A "NO" response to any of the following disqualifies the patient from study entry.  
 
  Yes      No  
6.  Able to be off prednisone or other systemic immunosuppressive medications for at least 3 days 
prior to NK cell infusion (excluding preparative regimen pre -medications)       
7.  Sexually active females of child bearing potential and males with partners of child bearing 
potential must agree to use effective contraception during therapy and for 4 months after 
completion of therapy       
8.  Voluntary written consent prior to the performance of any research related procedures       
 
EXCLUSION CRITERIA  
A "YES" response to any of the following disqualifies the patient from study entry.  
  Yes      No  
9.  Acute leukemias of ambiguous lineage       
10.  Pregnant or breastfeeding       
11.  Active autoimmune disease  requiring systemic immunosuppressive therapy        
12.  History of severe asthma and currently on systemic chronic medications (mild asthma requiring 
inhaled steroids only is eligible)       
13.  New or progressive pulmonary infiltrates on screening chest x -ray or chest CT scan unless 
cleared for study by [CONTACT_625263] . Infiltrates attributed to infection must be stable/improving (with 
associated clinical improvement) after 1 week of appropriate therapy (4 weeks for presumed or 
documented fungal infections )      
14.  Uncontrolled bacterial, fungal or viral infections including HIV -1/2 or active hepatitis C/B - chronic 
asymptom atic viral hepatitis is allowed .      
15.  Received any investigational agent within the 14 days before the start of study treatment (1st 
dose of fludarabine)       
16.  Prior ALT -803      
 
Having obtained consent and reviewed each of the inclusion/exclusion criteria, I verify that this patient is  eligible. 
 
            
Signature [CONTACT_625265]2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 47  of 52  CPRC #2016LS056  Appendix II – Eligibility Checklist – Donor   
Haploidentical Donor Natural Killer (NK) Cell Infusion with Subcutaneous ALT -803 in Adults with 
Refractory or Relapsed Acute Myelogenous Leukemia (AML)   
 
Donor  Eligibility Checklist – page 1 of 1 
Donor  initials           
 
INCLUSION CRITERIA  
A "NO" response to any of the following disqualifies the donor from study entry.  
  Yes   No  
1.  HLA-haploidentical related donor (aged 12 to 75 years) with donor/recipi[INVESTIGATOR_625236] a minimum of intermediate resolution DNA based Class I typi[INVESTIGATOR_151592] A and 
B locus  (at least 2/4 class I allele) .       
2.  Body weight of at least 40 kilograms       
3.  In general good health as determined by [CONTACT_136395]       
4.  Adequate organ function defined as:  
• Hematologic: hemoglobin, WBC, platelet within 10% of upper and lower limit of 
normal range of test (gender based for hemoglobin)  
 Hepatic:  ALT < 2 x upper limit of normal,  
  Renal:  serum creatinine < 1.8 mg/dl       
5.  Performance of a donor infectious disease screen panel including CMV Antibody, 
Hepatitis B Surface Antigen, Hepatitis B Core Antibody, Hepatitis C Antibody, HIV 1/2 
Antibody, HTLVA 1/2 Antibody, Treponema  and Trypanosoma Cruzi (T. Cruzi) plus 
HBV, HCV, WNV, HIV by [CONTACT_201863] (NAT);  or per current standard 
institutional donor screen – must be negative for HIV and active hepatitis B       
6.  Not pregnant - females of childbearing potential must have a negati ve pregnancy test 
within 7 days of apheresis       
7.  Voluntary written consent (and assent if donor < 18 years of age) prior to the 
performance of any research rela ted procedure       
 
 
         
Signature [CONTACT_625266]2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 48  of 52  CPRC #2016LS056  Appendix III - Performance Status Scale  
 
KARNOFSKY  PERFORMANCE STATUS SCALE  
Percentage   
100 Normal, no complaints, no evidence of disease  
90 Able to carry on normal activity; minor signs or symptoms of disease  
80 Normal activity with effort; some signs or symptoms of disease  
70 Cares for self; unable to carry on normal activity or do active work  
[ADDRESS_833033] of his/her needs  
50 Requires considerable assistance and frequent medical care  
40 Disabled; requires special care and assistance  
30 Severely disabled, hospi[INVESTIGATOR_374] . Death not imminent  
20 Very sick, hospi[INVESTIGATOR_20545], active supportive treatment necessary  
10 Moribund, fatal processes, progressing rapi[INVESTIGATOR_375]  
0 Dead  
 
REFERENCE    
Karnofsky DA:  Meaningful clinical classification of therapeutic responses to anti -cancer drugs . Editorial:  Clin Pharmacol Ther  
2:709- 712, 1961.  
 
 
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 49  of 52  CPRC #2016LS056  Appendix IV – Expected Toxicities of the Preparative Regimen  
 
Cyclophosphamide – 
Common  Less Common  Rare, but may be serious  
• low white blood cell count with 
increased risk of infection  
• hair loss or thinning, including face 
and body hair (usually grows back after treatment)  
• nausea  
• vomiting  
• loss of appetite  
• sores in mouth or on lips  
• bleeding from bladder, with blood in urine  
• diarrhea  
• long-term or short -term infertility 
(inability to have children) in 
women and men  • low platelet count (mild) 
with increased risk of 
bleeding  
• darkening of nail beds  
• acne  
• tiredness  
• infection 
• fetal changes if you 
become pregnant while 
taking 
cyclophosphamide  
 • heart problems with high doses, with chest pain, 
shortness of breath, or swollen feet  
• severe allergic reactions  
• skin rash  
• scarring of bladder  
• kidney damage (renal tubular necrosis) which can 
lead to kidney failure  
• heart damage, with trouble getting your breath, swelling of feet, rapid weight gain  
• scarring of lung tissue, with cough and shortness of breath  
• second cancer, which can happen years after 
taking this drug  
• death from infection, bleeding, heart failure, 
allergic reaction, or other causes  
 
Fludarabine - 
Common  Less Common  Rare, but may be serious  
• low white blood cell count with 
increased risk of infection  
• low platelet count with increased risk of bleeding  
• low red blood cell count (anemia) 
with tiredness and weakness  
• tiredness (fatigue)  
• nausea  
• vomiting  
• fever and chills  
• infection • pneumonia  
• diarrhea  
• loss of appetite  
• weakness  
• pain 
 • numbness and tingling in hands and/or feet 
related to irritation of nerves  
• changes in vision  
• agitation  
• confusion  
• clumsiness  
• seizures  
• coma  
• cough  
• trouble breathing  
• intestinal bleeding 
• weakness  
• death due to effects on the brain, infection, 
bleeding, severe anemia, skin blistering, or other 
causes  
 
 
  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 50  of 52  CPRC #2016LS056  Appendix V – Targeted Expected Toxicities  Worksheet  
MT2016- 05                                                         CTCAE v4            Refer to Section 12.2 for time points   
 Patient Initials:  _______ Date of Assessment:  _________     Assessment Time point:  _________      
Toxicity  Grade 0  Grade 1  Grade 2  Grade 3  Grade 4  
Infusion related 
reaction (NK 
cells) None  Mild transient reaction; 
infusion interruption not 
indicated; intervention not 
indicated  Therapy or infusion interruption 
indicated but responds promptly to 
symptomatic treatment (e.g., 
antihistamines, NSAIDS, narcotics, 
IV fluids); prophylactic medications indicated for ≤ 24 hrs  Prolonged (e.g., not rapi[INVESTIGATOR_38194]/or brief interruption 
of infusion); recurrence of symptoms 
following initial improvement; hospi[INVESTIGATOR_625237]-threatening consequences; 
urgent intervention indicated  
ALT-803 Injection 
site reaction  None  Tenderness with or 
without associated symptoms (e.g., warmth, 
erythema, itching)  Pain; lipodystrophy; e dema; 
phlebitis  Ulceration or necrosis; severe 
tissue damage; operative intervention indicated  Life-threatening consequences; 
urgent intervention indicated  
Dyspnea  None or  
no change  Shortness of breath with 
moderate exertion  Shortness of breath with minimal 
exertion; limiting instrumental ADL  Shortness of breath at rest;  
limiting self care ADL  Life-threatening consequences; 
urgent intervention indicated  
Hypoxia  None  ………………  Decreased O 2 saturation with 
exercise (e.g., pulse oximeter < 88%) intermittent supplemental 
oxygen  Decreased oxygen saturation at 
rest (e.g., pulse oximeter < 88% or PaO
2 ≤ 55 mm Hg)  Life-threatening airway  
compromise; urgent  
intervention indicated (e.g., 
tracheotomy  or intubation)  
Fever  None  38.0 - 39.0◦ C (100.4 -
102.2◦ F)  > 39.0 - 40.0◦C (102.3 - 104.0◦F)  > 40.0 ◦ C (>104.0◦ F) for ≤ 24 hrs  > 40.0 ◦ C (>104.0◦ F) for > 24 
hrs 
Chills  None  Mild sensation of cold; 
shivering; chattering of teeth  Moderate tremor of the entire body; 
narcotics indicated  Severe or prolonged, not  
responsive to narcotics  ………………………  
Hypertension  None  Pre-hypertension (systolic 
BP 120 - 139 mm Hg or 
diastolic BP 80 - 89 mm 
Hg) Stage 1 hypertension (systolic BP 
140 - 159 mm Hg or diastolic BP 90 - 
99 mm Hg); medical intervention indicated; recurrent or persistent ≥ 24 hrs); symptomatic increase by 
>20 mm Hg (diastolic) or to >140/90 
mm Hg if previously WNL; 
monotherapy indicated.  Stage 2 hypertension (systolic BP 
≥ 160 mm Hg or diastolic BP ≥ 100 mm Hg); medical intervention indicated; more than one drug or more intensive therapy than previously used indicated.  Life-threatening  
consequences (e.g.,  
malignant hypertension,  
transient or permanent  
neurologic deficit,  
hypertensive crisis); urgent 
intervention indicated.  
Hypotension  None  Asymptomatic, intervention  
not indicated  Non-urgent medical  
intervention indicated  Medical intervention or  
hospi[INVESTIGATOR_80157]-threatening and urgent 
intervention indicated  
Edema  None  Localized to dependent 
areas, no disability or 
functional impairment  Moderate localized edema  
and intervention indicated;  
limiting instrumental ADL  Severe localized edema and 
intervention indicated; limiting self 
care ADL  ………………………  
Pneumonitis  None  Asymptomatic; clinical or 
diagnostic observations 
only; intervention not 
indicated  Symptomatic; medical  
intervention indicated; limiting instrumental ADL  Severe symptoms; limiting self 
care ADL; oxygen indicated Life-threatening respi[INVESTIGATOR_62616]; urgent interventi on indicated (e.g. 
intubation or tracheotomy)  
Headache  None  Mild pain  Moderate pain; limiting 
instrumental ADL  Severe pain; limiting self care 
ADL ………………………  
Confusion 
(Altered Mental 
Status)  None  Mild disorientation  Moderate disorientation; limiting 
instrumental ADL  Severe disorientation; limiting self 
care ADL  Life-threatening  
consequences; urgent 
intervention indicated  
Rash  None  Covering < 10% body 
surface area (BSA)  Covering 10 -30% body surface 
area (BSA)  >30% body surface area (BSA)  Generalized exfoliative, 
ulcerative, or bullous dermatitis  
Gait Disturbance  None  Mild change in gait (eg, 
wide-based, limpi[INVESTIGATOR_625238])  Moderate change in gait (eg, wide -
based, limpi[INVESTIGATOR_575621]); assistance device indicated;  
limiting instrumental ADL  Disabling; limiting self care ADL  ………………………  
 
 
Person Completing Form:        ADL = activities of daily living  
  
MT2016- 05:  Haploidentical NK Cells and ALT-803 In Adults with Refractory or Relapsed AML   
 
   
January 22, 2019  Page 51  of 52  CPRC #2016LS056  Appendix VI – ALT-[ADDRESS_833034] -injection for  the Day 0 
injection will be the same date as date of injection for the Day +5 injection and both forms will be completed assessing the 
form’s targeted injection site.  If at Day [ADDRESS_833035] data for 
items 1 -4 daily until the reaction resolves. . 
  For inpatients, the diary is completed by [CONTACT_3462].  
 
 
Patient Number *  Date of Study Drug Injection * ________/_________/________  *To be completed by [CONTACT_779].  
Please answer all questions below daily  for 7 days , beginning with day of treatment.  Be sure to  bring back this completed diary to your next clinic visit.  
 
 Instructions  Day of Study 
Drug Injection  
____/____/_________  Day [ADDRESS_833036] Injection  
____/____/_________  Day [ADDRESS_833037] Injection  
____/____/_________  Day [ADDRESS_833038] Injection  
____/____/_________  Day [ADDRESS_833039] Injection  
____/____/________  Day [ADDRESS_833040] Injection  
___/___/________  Day [ADDRESS_833041] Injection  
____/____/_________  
 
1. Is there redness at 
the injection site?  
 Check:  
Yes  or  No 
If ye s, measure longest 
diameter in c m Yes  No  
 
________cm Yes  No  
 ________cm Yes  No  
 ________cm Yes  No  
 ________cm Yes  No  
 ________cm Yes  No  
 ________cm Yes  No  
 ________cm 
 
2. Is there firmness or 
swelling at the 
injection site?  Check:  
Yes  or  No 
 Yes  No  
 Yes  No  
 Yes  No  
 Yes  No  
 Yes  No  
 Yes  No  
 Yes  No  
 
 
3. Have you 
experienced any pain  
or itching  at the 
injection site?  Check:  
Yes  or  No 
If yes, tell us if the pain 
and/or itching is mild, 
moderate or severe   Pain   Itch  
Mild           Mild  
Mod           Mod  
Severe      Severe   Pain   Itch  
Mild           Mild  
Mod           Mod  
Severe      Severe   Pain   Itch  
Mild           Mild  
Mod           Mod  
Severe      Severe   Pain   Itch  
Mild           Mild  
Mod           Mod  
Severe     Severe   Pain   Itch  
Mild           Mild  
Mod           Mod  
Severe      Severe   Pain   Itch  
Mild           Mild  
Mod           Mod  
Severe      Severe   Pain   Itch  
Mild           Mild  
Mod           Mod  
Severe      Severe  
 
4. Have you taken or 
applied any 
medication for 
injection site pain or 
itching ? Check:  
Yes  or  No 
Provide name [CONTACT_119311](s) Yes  No 
Name (s): 
 Yes  No 
Name (s): 
 Yes  No 
Name:  
 Yes  No 
Name:  
 Yes  No 
Name:  
 Yes  No 
Name:  
 Yes  No 
Name:  
 
 
5. Have you 
experienced any 
chills?  
 Check:  
Yes  or  No 
If yes, tell us if the 
chills are  mild, 
moderate or severe  Yes  No 
       Mild  
Moderate  
       Severe  Yes  No 
       Mild  
Moderate  
       Severe  Yes  No 
       Mild  
Moderate  
       Severe  Yes  No 
       Mild  
Moderate  
       Severe  Yes  No 
       Mild  
Moderate  
       Severe  Yes  No 
       Mild  
Moderate  
       Severe  Yes  No 
       Mild  
Moderate  
       Severe  
 
6. Record your daily 
temperature  upon 
waking  
 (do not drink anything 5 
minutes before taking your 
temperature)  
  
Check:  
Yes  or  No 
If your temperature is 
101° F for more than 
24 hours, call your 
doctor.  
 Yes  No 
________ °F 
 
Time:  
____:____    
AM / PM  Yes  No 
________ °F 
 
Time:  
____:____  
AM / PM  Yes  No 
________ °F 
 
Time:  
____:____  
AM / PM  Yes  No 
________ °F 
 
Time:  
____:____  
AM / PM  Yes  No 
________ °F 
 
Time:  
____:____  
AM / PM  Yes  No 
________ °F 
 
Time:  
____:____  
AM / PM  Yes  No 
________ °F 
 
Time:  
____:____  
AM / PM  
Grading Injection Site Pain  or Itching        Grading Chills  
Mild – Noticeable, does not interfere with activity       Mild – Mild sensitive of cold, shivering, chattering of teeth 
Moderate – Interferes with activity, limiting activities of daily living     Moderate – Moderate tremor of entire body, medication taken  
Severe – Severely limiting self -care activities of d aily living, incapacitating     Severe – Prolonged or severe, does not respond to medication  
 